TR201615312A1 - Antiviral Pharmaceutical Compositions - Google Patents
Antiviral Pharmaceutical Compositions Download PDFInfo
- Publication number
- TR201615312A1 TR201615312A1 TR2016/15312A TR201615312A TR201615312A1 TR 201615312 A1 TR201615312 A1 TR 201615312A1 TR 2016/15312 A TR2016/15312 A TR 2016/15312A TR 201615312 A TR201615312 A TR 201615312A TR 201615312 A1 TR201615312 A1 TR 201615312A1
- Authority
- TR
- Turkey
- Prior art keywords
- release
- agent
- sodium
- acid
- pharmaceutical composition
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 21
- 239000013543 active substance Substances 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 208000007514 Herpes zoster Diseases 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 208000001688 Herpes Genitalis Diseases 0.000 claims abstract description 8
- 201000004946 genital herpes Diseases 0.000 claims abstract description 8
- 238000009097 single-agent therapy Methods 0.000 claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims abstract description 5
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims abstract description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims abstract description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims abstract description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims abstract description 3
- -1 controlled release Substances 0.000 claims description 62
- 239000008187 granular material Substances 0.000 claims description 25
- 239000003826 tablet Substances 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 20
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 14
- 229960004396 famciclovir Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000006188 syrup Substances 0.000 claims description 10
- 235000020357 syrup Nutrition 0.000 claims description 10
- 230000003111 delayed effect Effects 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 5
- 238000013265 extended release Methods 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 229960001179 penciclovir Drugs 0.000 claims description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 229940093257 valacyclovir Drugs 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 239000007894 caplet Substances 0.000 claims description 2
- 239000007911 effervescent powder Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 229960005102 foscarnet Drugs 0.000 claims description 2
- 229960004716 idoxuridine Drugs 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229960003962 trifluridine Drugs 0.000 claims description 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 2
- 239000004562 water dispersible granule Substances 0.000 claims description 2
- 238000002636 symptomatic treatment Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 79
- 239000000126 substance Substances 0.000 description 54
- 239000003795 chemical substances by application Substances 0.000 description 36
- 238000000034 method Methods 0.000 description 23
- 239000003814 drug Substances 0.000 description 17
- 238000005469 granulation Methods 0.000 description 17
- 230000003179 granulation Effects 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 16
- 229920001223 polyethylene glycol Polymers 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 12
- 239000010408 film Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 108010010803 Gelatin Proteins 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 229920000159 gelatin Polymers 0.000 description 11
- 239000008273 gelatin Substances 0.000 description 11
- 229940014259 gelatin Drugs 0.000 description 11
- 235000019322 gelatine Nutrition 0.000 description 11
- 235000011852 gelatine desserts Nutrition 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 10
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 10
- 235000019271 petrolatum Nutrition 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 239000007787 solid Chemical group 0.000 description 10
- 229960002920 sorbitol Drugs 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 9
- 235000010356 sorbitol Nutrition 0.000 description 9
- 239000000600 sorbitol Substances 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 229960005150 glycerol Drugs 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 229960004793 sucrose Drugs 0.000 description 8
- 229920001285 xanthan gum Polymers 0.000 description 8
- 235000010493 xanthan gum Nutrition 0.000 description 8
- 239000000230 xanthan gum Substances 0.000 description 8
- 229940082509 xanthan gum Drugs 0.000 description 8
- 239000004264 Petrolatum Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- 235000010216 calcium carbonate Nutrition 0.000 description 7
- 239000004359 castor oil Substances 0.000 description 7
- 235000019438 castor oil Nutrition 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 7
- 229920000609 methyl cellulose Polymers 0.000 description 7
- 235000010981 methylcellulose Nutrition 0.000 description 7
- 239000001923 methylcellulose Substances 0.000 description 7
- 229960002900 methylcellulose Drugs 0.000 description 7
- 229940066842 petrolatum Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 235000019325 ethyl cellulose Nutrition 0.000 description 6
- 229920001249 ethyl cellulose Polymers 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 6
- 235000010234 sodium benzoate Nutrition 0.000 description 6
- 239000004299 sodium benzoate Substances 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 5
- 239000005995 Aluminium silicate Substances 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920002907 Guar gum Polymers 0.000 description 5
- 229920000084 Gum arabic Polymers 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 5
- 239000004166 Lanolin Substances 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 5
- 235000010489 acacia gum Nutrition 0.000 description 5
- 239000000205 acacia gum Substances 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 150000004781 alginic acids Chemical class 0.000 description 5
- 235000012211 aluminium silicate Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 description 5
- 238000007908 dry granulation Methods 0.000 description 5
- 229960001484 edetic acid Drugs 0.000 description 5
- 229960001031 glucose Drugs 0.000 description 5
- 229940075507 glyceryl monostearate Drugs 0.000 description 5
- 235000010417 guar gum Nutrition 0.000 description 5
- 239000000665 guar gum Substances 0.000 description 5
- 229960002154 guar gum Drugs 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 5
- 235000019388 lanolin Nutrition 0.000 description 5
- 229940039717 lanolin Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960004418 trolamine Drugs 0.000 description 5
- 239000000811 xylitol Substances 0.000 description 5
- 235000010447 xylitol Nutrition 0.000 description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 5
- 229960002675 xylitol Drugs 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229920002675 Polyoxyl Polymers 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 239000000783 alginic acid Substances 0.000 description 4
- 229960001126 alginic acid Drugs 0.000 description 4
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 4
- 229940063655 aluminum stearate Drugs 0.000 description 4
- 239000002518 antifoaming agent Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N beta-Carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- 229940081733 cetearyl alcohol Drugs 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 4
- 229960004667 ethyl cellulose Drugs 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 229960003511 macrogol Drugs 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 229960001855 mannitol Drugs 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 235000010199 sorbic acid Nutrition 0.000 description 4
- 239000004334 sorbic acid Substances 0.000 description 4
- 229940075582 sorbic acid Drugs 0.000 description 4
- 229940012831 stearyl alcohol Drugs 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- 239000004115 Sodium Silicate Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000000181 anti-adherent effect Effects 0.000 description 3
- 239000003911 antiadherent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000007931 coated granule Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 229940043237 diethanolamine Drugs 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 239000000905 isomalt Substances 0.000 description 3
- 235000010439 isomalt Nutrition 0.000 description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 3
- 229960000829 kaolin Drugs 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000001055 magnesium Nutrition 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 239000000391 magnesium silicate Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229960003194 meglumine Drugs 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 229940068965 polysorbates Drugs 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 3
- 229910052911 sodium silicate Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229960004274 stearic acid Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 239000003871 white petrolatum Substances 0.000 description 3
- 229940045860 white wax Drugs 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical class CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- IOUUIFSIQMVYKP-UHFFFAOYSA-N Tetradecyl acetate Chemical compound CCCCCCCCCCCCCCOC(C)=O IOUUIFSIQMVYKP-UHFFFAOYSA-N 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 229940081735 acetylcellulose Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229940043379 ammonium hydroxide Drugs 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 229960002645 boric acid Drugs 0.000 description 2
- VHEMBTYWURNBQQ-UHFFFAOYSA-N butanoic acid;phthalic acid Chemical compound CCCC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O VHEMBTYWURNBQQ-UHFFFAOYSA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- ILWNTWRKKKGJCG-UHFFFAOYSA-L calcium;sulfate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]S([O-])(=O)=O ILWNTWRKKKGJCG-UHFFFAOYSA-L 0.000 description 2
- 229960001777 castor oil Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 229920001727 cellulose butyrate Polymers 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 239000007765 cera alba Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 229920003087 methylethyl cellulose Polymers 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 229960004838 phosphoric acid Drugs 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000003711 photoprotective effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-M phthalate(1-) Chemical compound OC(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-M 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 229940001593 sodium carbonate Drugs 0.000 description 2
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 description 2
- 229940032158 sodium silicate Drugs 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000009475 tablet pressing Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- URBTWKYNKXLBSU-UHFFFAOYSA-N 18-(18-oxooctadecoxy)octadecanal Chemical compound O=CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC=O URBTWKYNKXLBSU-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- VNFYMAPAENTMMO-UHFFFAOYSA-N 5-chloro-2-methylquinoline Chemical compound ClC1=CC=CC2=NC(C)=CC=C21 VNFYMAPAENTMMO-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- WWXUGNUFCNYMFK-UHFFFAOYSA-N Acetyl citrate Chemical compound CC(=O)OC(=O)CC(O)(C(O)=O)CC(O)=O WWXUGNUFCNYMFK-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000021537 Beetroot Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Chemical class 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- ALWNROUGZXQZCX-UHFFFAOYSA-N [Ca].C=C Chemical group [Ca].C=C ALWNROUGZXQZCX-UHFFFAOYSA-N 0.000 description 1
- XLLNINGEDIOQGQ-UHFFFAOYSA-N [acetyloxy(hydroxy)phosphoryl] acetate Chemical compound CC(=O)OP(O)(=O)OC(C)=O XLLNINGEDIOQGQ-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229940008075 allyl sulfide Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 description 1
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940052651 anticholinergic tertiary amines Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940042397 direct acting antivirals cyclic amines Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- SIGAZICKKNXYRV-XXAVUKJNSA-L disodium 4-[[(Z)-octadec-9-enoyl]amino]oxy-4-oxo-3-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCC\C=C/CCCCCCCC(=O)NOC(=O)C(S([O-])(=O)=O)CC([O-])=O SIGAZICKKNXYRV-XXAVUKJNSA-L 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229930190179 eucalyptal Natural products 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000001034 iron oxide pigment Substances 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- OGGIFKYAUCDPFX-UHFFFAOYSA-N n,n-diethyldodecan-1-amine oxide Chemical compound CCCCCCCCCCCC[N+]([O-])(CC)CC OGGIFKYAUCDPFX-UHFFFAOYSA-N 0.000 description 1
- WIBFFTLQMKKBLZ-SEYXRHQNSA-N n-butyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCC WIBFFTLQMKKBLZ-SEYXRHQNSA-N 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940073555 nonoxynol-10 Drugs 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000010663 parsley oil Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000008191 permeabilizing agent Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 229910001388 sodium aluminate Inorganic materials 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229950003429 sorbitan palmitate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229940012185 zinc palmitate Drugs 0.000 description 1
- LPEBYPDZMWMCLZ-CVBJKYQLSA-L zinc;(z)-octadec-9-enoate Chemical compound [Zn+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O LPEBYPDZMWMCLZ-CVBJKYQLSA-L 0.000 description 1
- GJAPSKMAVXDBIU-UHFFFAOYSA-L zinc;hexadecanoate Chemical compound [Zn+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O GJAPSKMAVXDBIU-UHFFFAOYSA-L 0.000 description 1
Abstract
Mevcut buluş; Herpes zoster (zona), HIV enfeksiyonlu hastalardaki tekrarlayan herpes simpleksin tedavisinde, epstein-Barr virüsü, genital herpes, genital herpes profilaksisi, herpes simplex virüs tip 1, herpes simplex virüs tip 2, postherpetik nöralji, varicella-zoster virüsünün profilaktik ve/veya semptomatik ve/veya terapötik tedavisinde kullanılmak üzere antiviral özellikteki uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevlerinin monoterapi olarak tek başına kullanıldığı ve/veya bu etken maddenin diğer uygun aktif ajan/lar ile kombine tedavi olarak kullanıldığı farmasötik bileşim/ler ile ilgilidir.The present invention includes; Herpes zoster (shingles), epstein-Barr virus, genital herpes, genital herpes prophylaxis, herpes simplex virus type 1, herpes simplex virus type 2, postherpetic neuralgia, varicella-zoster virus prophylactic and / or symptomatic and / or suitable antiviral active ingredient and / or pharmaceutically acceptable derivatives thereof for use in therapeutic treatment, as monotherapy alone and / or in combination with other suitable active agents.
Description
TARIFNAME ANTIVIRAL FARMASÖTIK TERKIPLER BULUSUN ILGILI OLDUGU ALAN Mevcut bulus; Herpes zoster (zona), HIV enfeksiyonlu hastalardaki tekrarlayan herpes simpleksin tedavisinde, epstein-Barr virüsü, genital herpes, genital herpes profilaksisi, herpes simplex virüs tip 1, herpes siinplex virüs tip 2, postherpetik nöralji, varicella-zoster virüsünün profilaktik ve/veya semptomatik ve/veya terapötik tedavisinde kullanilmak üzere antiviral özellikteki uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevlerinin monoterapi olarak tek basina kullanildigi ve/veya bu etken maddenin diger uygun aktif ajan/lar ile koinbine tedavi olarak kullanildigi farmasötik bilesim/ler ile Mevcut bulus; antiviral özellikteki uygun etken maddenin Famsiklovir, 2- olarak kabul edilebilir türevleri oldugu, monoterapi olarak tek basina kullanildigi ve/veya bu etken maddenin diger uygun ajan/lar ile kombine tedavi olarak kullanildigi farmasötik bilesim/ler ile ilgilidir. DESCRIPTION ANTIVIRAL PHARMACEUTICAL COMPOSITIONS FIELD OF THE INVENTION The present invention; Herpes zoster (shingles), recurrent herpes in HIV-infected patients simplex, epstein-Barr virus, genital herpes, genital herpes prophylaxis, herpes simplex virus type 1, herpes siinplex virus type 2, postherpetic neuralgia, varicella-zoster be used in the prophylactic and/or symptomatic and/or therapeutic treatment of suitable active substance with antiviral properties and/or pharmaceutically acceptable derivatives are used alone as monotherapy and/or other with the appropriate active agent(s) and the pharmaceutical composition(s) for which it is used as a treatment to coinbine. The present invention; Famciclovir, 2- have acceptable derivatives, are used alone as monotherapy, and/or pharmaceuticals where this active ingredient is used as a combined treatment with other suitable agent/s relates to the composition/s.
Formül 1: Ayrica bulus, Famsiklovir ve/veya farmasötik olarak kabul edilebilir türevleriiiiii monoterapi olarak tek basina kullanildigi veya bu etken maddenin diger uygun ajan/lar ile kombine tedavi olarak kullanildigi farmasötik bilesim/lerin oral yolla uygulainasi için uygun olan formülasyonlarini ve profilaktik ve/veya semptoinatik ve/veya terapötik kullanimlarini da kapsamaktadir. ÖNCEKI TEKNIK (TEKNIGIN BILINEN DURUMU) Hepatit B enfeksiyonu ise, halk arasinda sarilik olarak bilinen Hepatit yani "karaciger iltihaplanmasi" na yol açan, Hepadnaviridae virüs ailesinde yer alan Hepatit B virüsünün (HBV) karaciger dokusunda enfeksiyona yol açmasiyla ortaya çikan bir durumdur. Formula 1: In addition, the invention includes Famciclovir and/or its pharmaceutically acceptable derivativesiii It is used alone as monotherapy or when this active substance is combined with other suitable agent/s. for oral administration of pharmaceutical composition(s) used as combination therapy appropriate formulations and prophylactic and/or symptomatic and/or therapeutic includes their use. PRIOR ART (KNOWN STATE OF THE ART) Hepatitis B infection, on the other hand, is hepatitis, which is known as jaundice among the people. Hepatitis B virus, which belongs to the Hepadnaviridae family of viruses, causes (HBV) is a condition that occurs when it causes infection in the liver tissue.
HBV, bir DNA Virüsü olmasina karsin “revers transkriptaz” enzimini kodlar ve bu enzim sayesinde RNA aracisi üzerinden replike olur (Summers ve Mason. Cell 29: 403-415, 1982). Eiifekte hücre çekirdeginde bir minikromozom seklinde bulunur. Kovalent bagli çemberscl DNA adi verilen, replikasyon ve transkripsiyon esnasinda araci molekül özelligi tasiyan bir DNA zinciri üzerinden meydana gelen, karmasik bir replikasyon stratejisine sahiptir. Although HBV is a DNA Virus, it encodes the "reverse transcriptase" enzyme and this enzyme replicates via the RNA mediator (Summers and Mason. Cell 29: 403-415, 1982). It is found as a minichromosome in the eifected cell nucleus. covalently bound Intermediate molecule property called circular DNA during replication and transcription It has a complex replication strategy that consists of a DNA strand carrying has.
Kronik hepatit B, bu gün dünyada 400 milyon kisiyi ilgilendiren önemli bir saglik problemi ve en yaygin enfeksiyon hastaliklarindan biridir. Dünya Saglik Örgütü`ne göre, dünya nüfusunun üçte biri hepatit B virüsü ile enfektedir ve bunlarin % 5°i kronik hastadir. Chronic hepatitis B is an important health problem that concerns 400 million people in the world today. problem and one of the most common infectious diseases. According to the World Health Organization, One third of the world's population is infected with the hepatitis B virus and 5% of them are chronically ill.
Bu kronik hastalarin yaklasik dörtte biri, ölümcül karaciger hastaliklari olan karaciger sirozu ve karaciger kanserine ilerlemektedir. Nihayetinde yilda 1 milyon kisi hepatit B virüsü nedeniyle ölmektedir. Virüs vücuda ilk kez girdiginde siddetli belirtiler ve sarilik yapabilecegi gibi hiçbir belirti de vermeyebilir. Enfeksiyon sonrasi seyir tam sifa ve ömür boyu süren bagisiklik olabilecegi gibi kroniklesme ve kalici karaciger hastaligina ve karaciger kanserine dönüsüm de söz konusu olabilir. Kroniklesen hepatit B enfeksiyonu karaciger yetmezligi, siroz ve karaciger kanseri riskini önemli oranda artirir. Dünya Saglik Örgütü tarafindan, Hepatit B virüsünün (HBV) dünya çapindaki hepatosellüler karsinom vakalarinin %80' inden sorumlu oldugu ve insani etkileyen karsinojenler arasinda sigaradan sonra ikinci sirada oldugu bildirilmistir (WHO/CDS/CSR/LYO/2002,2: Hepatitis Dünya genelinde morbidite ve ölüm oraniyla ciddi karaciger hastaliklari arasinda yer alan Kronik hepatit B virüs enfeksiyonu tedavisinde kullanilan farmasötik bilesikler; l. Immün modülatörler - Standart interferonlar ve pegile interferonlar 2. Viral polimeraz inhibitörleridir. About a quarter of these chronic patients have liver disease with fatal liver diseases. progresses to cirrhosis and liver cancer. Ultimately, 1 million people a year with hepatitis B dies from the virus. Severe symptoms and jaundice when the virus first enters the body It may not give any symptoms as well. Post-infection course full healing and life There may be long-lasting immunity, as well as chronicity and permanent liver disease and There may also be a transformation into liver cancer. chronic hepatitis B infection It significantly increases the risk of liver failure, cirrhosis and liver cancer. World Health Worldwide hepatocellular carcinoma of the hepatitis B virus (HBV) It is among the carcinogens that are responsible for 80% of the cases and affect humans. It has been reported to be in the second place after smoking (WHO/CDS/CSR/LYO/2002.2: Hepatitis It is among the serious liver diseases with morbidity and death rate worldwide. Pharmaceutical compounds used in the treatment of chronic hepatitis B virus infection; l. Immune modulators - Standard interferons and pegylated interferons 2. They are viral polymerase inhibitors.
I Nükleozid ve nükleotid analoglari Uzun zamandir kullanilan interferon alfa (IFN) ile hastalarin ancak yaklasik üçte birinde virolojik yanit alinabilmekte ve sik görülen yan etkiler bu ilacin kullanimini guçlestirmektedir. I Nucleoside and nucleotide analogues Only about one-third of patients with long-term interferon alpha (IFN) virological response can be obtained and common side effects may prevent the use of this drug. strengthens it.
Test edilen nükleozid ve nükleotid analoglarina örnek olarak pensiklovir ve kati formu (FCV) [Vere Hodge, Antiviral Chem Chemother 4: 67-84, 1993; Boyd ve ark., Antiviral Chem Hepatitis 3: [Severini ve ark, Antimicrobial Agents verilebilir. Examples of nucleoside and nucleotide analogues tested are penciclovir and its solid form. (FCV) [Vere Hodge, Antiviral Chem Chemother 4: 67-84, 1993; Boyd et al., Antiviral Chem Hepatitis 3: [Severini et al, Antimicrobial Agents can be given.
Zona deri sinirlerinin agrili döküntülü iltihabidir. Herpes zoster virüsü ile meydana gelir. Shingles is an inflammation of the skin nerves with a painful rash. It is caused by the herpes zoster virus.
Herpes zoster Virüsü çocuk çagda bulasir ve ilk olarak suçiçegi yapar daha sonra sinir hücreleri içinde saklanir yillar sonra immün sistemin zayifladigi bir anda sinir iltihabi yapar. Herpes zoster Virus is transmitted in childhood and firstly it causes chickenpox, then it becomes nervous. years later, when the immune system weakens, it causes nerve inflammation.
Dünyada yaygin olarak bulunan herpes simpleks virüsünün tek dogal kaynagi insandir. The only natural source of the herpes simplex virus, which is widespread in the world, is human.
Hastalik baslica enfekte doku ve salgilarla oral yoldan bulasir. Anneden geçen antikorlarin kaybolmasiyla birlikte yasamin ilk yillarinda primer enfeksiyonlar baslar. Iyilesmeden sonra antikorlarin olusmasina karsin virüs organizmadan ayrilmaz ve yasam boyu süren tasiyicilik hali ortaya çikar. Çocukluk çaginda primer enfeksiyon geçirilmezse daha ileri yaslarda enfeksiyon geçirilmez. Diger taraftan eriskinlerin %70-90”inda HSV-l antikorlari bulunmaktadir ( Topçu AW, Söyletir G, Doganay M: Infêlcsiyon Hastaliklari ve Mi'krobiyolojisi. The disease is transmitted orally, mainly through infected tissue and secretions. maternally transmitted antibodies With its disappearance, primary infections begin in the first years of life. after recovery Despite the formation of antibodies, the virus does not separate from the organism and is a lifelong carrier. still emerges. If there is no primary infection in childhood, infection is not passed. On the other hand, 70-90% of adults have HSV-1 antibodies. ( Topçu AW, Söyletir G, Doganay M: Infection Diseases and Microbiology.
Herpes simpleks Virüsü (HSV), dünyada en sik enfeksiyon yapan viruslardan birisidir. Herpes simplex virus (HSV) is one of the most common infectious viruses in the world.
HSV51erin tip 1 (HSV-l) ve tip 2 (HSV-2) olmak üzere iki ayri tipi vardir. En sik görülen (toplumun 0/o 857i) HSV-l enfeksiyonu, genital bölge disindaki deri ve mukozalarda hastaliga neden olur. HSV-Z ise genital ve anal bölge mukoza ve derisinde hastalik yapmaktadir. Herpes simpleks virüsü (HSV), bagisiklik yetmezligi olan hastalarda, bagisiklik yetmezliginin derecesi ile dogru orantili bir sekilde daha sik, daha agir ve daha kronik infeksiyonlar olusturmaktadir. There are two different types of HSV51s, type 1 (HSV-1) and type 2 (HSV-2). most common (0/o 857i of the society) HSV-1 infection in skin and mucous membranes outside the genital area causes illness. HSV-Z is a disease in the mucous and skin of the genital and anal region. doing. Herpes simplex virus (HSV), in immunocompromised patients, more frequently, more severely, and more frequently in direct proportion to the degree of immunodeficiency. chronic infections.
Virüslerin hücre içerisinde çogalmalarini zorlastiran ve böylece virüslere bagli hastaliklarin daha hafif bulgularla atlatilmasina olanak saglayan ilaçlar antiviral ilaçlardir. It makes it difficult for viruses to multiply in the cell and thus prevents viral diseases. Drugs that allow it to be overcome with milder symptoms are antiviral drugs.
Varisella-zoster virüs (VZV) iki farkli klinik tabloya neden olan bir infeksiyon etkenidir. Varicella-zoster virus (VZV) is an infectious agent that causes two different clinical pictures.
Varisella veya sik kullanilan adiyla suçiçegi; yaygin ekzantömatöz deri döküntüleriyle karakterli, ilimli seyir gösteren, bagisik olmayan kisilerin Virusla karsilasmasi sonucu olusan primer hastalik tablosudur. Zona veya herpes zoster ise organizmada primer infeksiyon sonrasi latent kalan VZV°nin rekürren infeksiyonudur. Varicella, or varicella, as it is commonly called; with diffuse exanthematous skin rashes Characterized as a result of exposure of people with a moderate course and not immune to the virus. is the primary disease. Primary infection in the organism if shingles or herpes zoster It is a recurrent infection of VZV, which remains latent after
Famsiklovir oral yoldan kullanilan antiviral bir ajandir. Pensiklovir adli antiviral ajanin ön ilacidir. Famsiklovir sindirim sisteminden kolay emilmekte ve kanda daha yüksek düzeylerde kalmaktadir. Bu özelliginde dolayi, valasiklovir gibi, daha uzun aralikli günlük dozlar seklinde kullanilabilmektedir (Rudnick CM, Hoekzenia GS. Neonatal herpes simplex degistirilmis salimli famsiklovir içeren farmasötik kompozisyonlardan bahsedilmektedir. Famciclovir is an orally administered antiviral agent. Precursor of penciclovir forensic antiviral agent it is medicine. Famciclovir is easily absorbed from the gastrointestinal tract and is higher in blood. levels remain. Because of this feature, like valaciclovir, longer interval daily It can be used in doses (Rudnick CM, Hoekzenia GS. Neonatal herpes simplex). Pharmaceutical compositions containing modified-release famciclovir are mentioned.
BULUSUN AÇIKLAMASI Mevcut bulus; Herpes zoster (zona), HIV enfeksiyonlu hastalardaki tekrarlayan herpes siinpleksin tedavisinde, epstein-Barr virüsü, genital herpes, genital herpes protilaksisi, herpes simplex virüs tip 1, herpes simplex virüs tip 2, postherpetik nöralji, varicella-zoster virüsünün profilaktik ve/veya semptomatik ve/veya terapötik tedavisinde kullanilmak üzere antiviral özellikteki uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevlerinin monoterapi olarak tek basina kullanildigi ve/veya bu etken maddenin diger uygun aktif ajan/lar ile kombine tedavi olarak kullanildigi farmasötik bilesim/ler ile Mevcut bulusun bir diger yönü; oral kullanilmak üzere antiviral özellikteki uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevlerinin monoterapi olarak tek basina kullanildigi ve/veya bu etken maddenin diger uygun aktif ajan/lar ile kombine tedavi olarak kullanildigi farmasötik bilesim/lerin hazirlanmasi ile ilgilidir. DESCRIPTION OF THE INVENTION The present invention; Herpes zoster (shingles), recurrent herpes in HIV-infected patients In the treatment of siinplexin, epstein-Barr virus, genital herpes, genital herpes prophylaxis, herpes simplex virus type 1, herpes simplex virus type 2, postherpetic neuralgia, varicella-zoster be used in the prophylactic and/or symptomatic and/or therapeutic treatment of suitable active substance with antiviral properties and/or pharmaceutically acceptable derivatives are used alone as monotherapy and/or other with pharmaceutical composition(s) used in combination therapy with appropriate active agent(s) Another aspect of the present invention is; suitable agent with antiviral properties for oral use substance and/or pharmaceutically acceptable derivatives alone as monotherapy used and/or combined treatment of this active substance with other suitable active agent/s It relates to the preparation of pharmaceutical composition(s) for which it is used.
Bulusta kullanilan antiviral özellikteki uygun etken madde bunlarla sinirli olmamakla birlikte; asiklovir, famsiklovir, foskarnet, pensiklovir, trifluridin, valasiklovir, idoksuridin ve/veya farmasötik olarak kabul edilebilir türevlerinin arasindan tercihen famsiklovir olarak seçilir. The appropriate active substance with antiviral properties used in the invention is not limited to these. together; acyclovir, famciclovir, foscarnet, penciclovir, trifluridine, valaciclovir, idoxuridine and/or pharmaceutically acceptable derivatives, preferably famciclovir is selected as.
Bulusta “farmasötik olarak kabul edilebilir türevleri” terimi ile farmasötik olarak kabul edilebilir uygun tuzlar, esterler, solvatlar, hidratlar, kompleksler, polimorflar, enantiyomerler, önilaçlar, asit adisyon tuzlari, analoglar, izomerler, rasematlar, amidler, enantiyomer tuzlari, bazik tuzlar, konjugeler, tautomerler, anhidratlar, anhidritler, bazlar, asitler, eterler, kristal ve amorf formlar veya serbest formlarindan bir veya daha fazlasi ifade edilmektedir. In the invention, the term "pharmaceutically acceptable derivatives" is defined as pharmaceutically acceptable. Suitable salts, esters, solvates, hydrates, complexes, polymorphs, enantiomers, prodrugs, acid addition salts, analogs, isomers, racemates, amides, enantiomer salts, basic salts, conjugates, tautomers, anhydrates, anhydrides, bases, one or more of acids, ethers, crystalline and amorphous forms or free forms is expressed.
Oral uygulama için hazirlanan farmasötik bilesim kati ya da sivi dozaj forrnlarinda olabilir. The pharmaceutical composition prepared for oral administration may be in solid or liquid dosage forms.
Bu dozaj formlari; tablet (kaplama içermeyen, çignenebilir, agizda çözünen, dagilabilen, suda dagilabilen, film kapli, tek tabakali, çift tabakali, barsakta açilan kaplamali, mini tablet, kontrollü salimli, sürekli salimli, hemen salimli, uzatilmis salimli, geciktirilmis salimli, degistirilmis salimli, bukkal), kapsül (sert, yumusak, enterik kapli, film kapli, kontrollü salimli, sürekli salimli, hemen salimli, uzatilmis salimli, geciktirilmis salimli, degistirilmis salimli), toz, kuru toz, granül, kaplet, disk, agizda çözünen film, yigin toz (çok dozlu), pellet, sase, suda dagilabilen toz, suda dagilabilen granül, efervesan tablet, efervesan granül, efervesan toz, mikrokapsül, dental tabletler, pilül, surup, solüsyon, süspansiyon, eliksir, damla, posyon, emülsiyon veya sprey gibi bir dozaj sekli halinde formüle edilebilir. These dosage forms are; tablet (uncoated, chewable, mouth soluble, dispersible, water dispersible, film coated, single layer, double layer, intestinal release coated, mini tablet, controlled release, sustained release, immediate release, extended release, delayed release release, modified release, buccal), capsule (hard, soft, enteric-coated, film-coated, controlled release, sustained release, immediate release, extended release, delayed release, modified release), powder, dry powder, granule, caplet, disc, mouth soluble film, bulk powder (multi-dose), pellet, sachet, water-dispersible powder, water-dispersible granule, effervescent tablet, effervescent granule, effervescent powder, microcapsule, dental tablets, pilula, syrup, solution, as a dosage form such as suspension, elixir, drops, position, emulsion, or spray. can be formulated.
Etkin madde ve yardimci maddeler toz halinde karistirilarak bitmis ürün elde edilir. Sase halinde formüle edilebilir. The finished product is obtained by mixing the active substance and auxiliary substances in powder form. chassis can be formulated.
Oral yolla uygulanmak üzere hazirlanan granüllerin bazilari yutularak, bazilari çignenerek, bazilari ise suda veya diger uygun bir sivi içinde çözülerek veya dagitilarak kullanilirlar. Some of the granules prepared for oral administration are swallowed, some are chewed, some are used by dissolving or dispersing in water or other suitable liquid.
Granüller bir veya daha fazla etkin madde, yardimci maddeler, gerekli ise renk ve koku verici maddeler de içerirler. Yardimci madde olmaksizin da hazirlanabilirler. Granüller tek doz veya çok dozlu olarak ambalajlanabilirler. Çok dozlu preparatlari, istenilen dozda alinabilmeleri için uygun bir ölçekle birlikte ambalajlanir. Tek doz granüller poset, kagit paket veya flakon gibi tek birimlik kaplarda sunulur. Üretimleri, ambalajlari, depolama ve dagitimlari mikrobiyal kontaminasyondan uzak olarak gerçeklestirilmelidir, Uçucu veya korunmasi gereken madde içeren granüller siki kapatilmis kaplarda muhafaza edilmelidir. Granules contain one or more active ingredients, excipients, color and fragrance if necessary. They also contain donor substances. They can also be prepared without any excipients. Granules single They can be packaged in dose or multidose form. Multi-dose preparations, at the desired dose They are packaged with a suitable scale so that they can be taken. Single dose granules bag, paper supplied in single-unit containers such as packs or vials. production, packaging, storage and their distribution should be carried out away from microbial contamination, Volatile or Granules containing substances to be protected should be stored in tightly closed containers.
Efêrvesan granüller.' Kaplanmamis granüllerdir. Genellikle asit maddeler, karbonatlar veya bikarbonatlar içeren ve su ile hizla reaksiyona girerek karbondioksit açiga çikaran granüllerdir. Uygulamadan önce suda çözülür veya dagitilir. Etkin madde tasiyicisi olarak kullanilirlar. Formülasyonlarinda sitrik asit, tartarik asit, fumarik asit gibi asit maddeler ile sodyum karbonat, sodyum bikarbonat ve sodyum bifosfat gibi alkali maddeler içerirler. Effervescent granules.' They are uncoated granules. Usually acid substances, carbonates or containing bicarbonates and reacting rapidly with water to release carbon dioxide are granules. It is dissolved or dispersed in water before application. As an active substance carrier they are used. It contains acidic substances such as citric acid, tartaric acid, fumaric acid in its formulations. they contain alkaline substances such as sodium carbonate, sodium bicarbonate and sodium biphosphate.
Kaplanmis granüller.' Çogunlukla çok dozlu preparatlardir ve çesitli yardiinci madde karisimlariyla bir veya daha fazla tabaka halinde kaplanmis granüllerden olusur. Kaplayici olarak kullanilan maddeler çogu kez çözelti veya süspansiyon seklinde ve sivi kisimlarinin buharlastirildigi kosullarda uygulanirKaplanmis granüllere, etkin maddenin uygun salim gösterdigini tespit etmek için uygun bir çözünme testi örnegin kati dozaj formlari için açiklanan testlerden biri uygulanabilir. Coated granules.' They are mostly multi-dose preparations and various excipients. It consists of granules coated in one or more layers with their mixture. Coater Substances used as solvents are often in the form of solutions or suspensions and Applied in conditions where it is evaporated Proper release of active substance to coated granules A suitable dissolution test, for example, for solid dosage forms one of the tests described can be applied.
Modifiye salim yapan granüller: Aktif madde veya maddelerin salim hizini, yerini veya zamanini modifiye etmek üzere tasarlanmis, özel yardimci maddeler içeren veya özel islemlerle hazirlanan, ayri ayri veya birlikte, kaplanmis ya da kaplanmamis granüllerdir. Modified release granules: The release rate, location or location of the active substance or substances. designed to modify the timing, containing special excipients, or They are coated or uncoated granules, individually or together, prepared by processes.
Bu granüller üzerinde, etkin maddenin salim tarzini göstermek için uygun bir çözünme testi uygulanir. A suitable dissolution on these granules to show the mode of release of the active substance. test is applied.
Mide ortamina dayanikli (gastro-resistant) granüller: Mide sivisinda dayanikli olan ve intestmal sivi içinde etkin maddenin (maddelerin) salimi için tasarlanmis, geciktirilmis salim yapan granüllerdir. Bu özellikleri, granüllerin mide sivisina dayanikli bir materyal ile kaplanmasiyla (enterik kapli granüller) veya uygun diger vasitalar ile saglanmaktadir. Bu granüller üzerinde, etkin maddenin uygun salim gösterdigini tespit etmek için uygun bir çözünme testi örnegin kati dozaj formlari için açiklanan testlerden biri uygulanabilir. Gastro-resistant granules: resistant to gastric fluid and Delayed, designed for the release of the active substance(s) in an intestinal fluid releasing granules. These properties are due to the fact that the granules are combined with a gastric fluid-resistant material. It is provided by coating (enteric coated granules) or by other suitable means. This an appropriate test on the granules to determine the appropriate release of the active substance. For example, one of the tests described for solid dosage forms can be applied.
Dozaj formlarinin hazirlanmasinda birçok teknikten yararlanilmaktadir. Bunlardan biri de granülasyon yöntemidir. Granülasyon; ince toz partiküllerin büyümesi seklinde tanimlanmaktadir. Farmasötik amaçli granülasyon; tabletleme için bir Ön hazirlik asamasidir, ayni zamanda, sert jelatin kapsüle doldurma veya granülün bir final ürün olarak bir pakete yerlestirilerek kullaniini amaciyla da uygulanmaktadir. Many techniques are used in the preparation of dosage forms. one of them granulation method. Granulation; as the growth of fine dust particles is defined. Granulation for pharmaceutical purposes; A preparation for tableting This is the stage of filling hard gelatin capsules or granules as a final product. It is also applied for the purpose of its use by being placed in a package.
Granülasyonun amaci, karisima istirak eden toz maddenin partiküllerinin birim ilacinin % miktarlarina esdeger olacak agirlikta bir ünite olusturmaktir. Farmasötik toz karisimlarin (etken madde veya yardimci maddeler) ayrismalarini engelleyerek bir ünite içerisinde homojen bir sekilde kalmalarini saglamak gerekmektedir bu da granülasyon ile mümkündür. The purpose of the granulation is to give the unit drug % of the particles of the powder substance participating in the mixture. is to create a unit of weight that will be equivalent to the quantities. Pharmaceutical powder mixes (active substance or auxiliary substances) in a unit by preventing their separation. It is necessary to ensure that they remain in a homogeneous form, this is achieved by granulation. possible.
Granülasyonda seçilecek yöntemler 3 ana kategoride siniflandirilabilir: yas granülasyon, kuru granülasyon ve diger granülasyon yöntemleri. The methods to be chosen in granulation can be classified in 3 main categories: wet granulation, dry granulation and other granulation methods.
Yas Granülasyon; Yas granülasyon yönteminde, yüksek hizli akiskan yatak granülasyon, püskürterek kurutma ve ekstrüsyon pelletleme yönteinleri kullanilmaktadir. Yas granülasyonda, etken inadde ve baglayici madde (solüsyon) belirli sürede karistirilir, yas olarak elenir ve akiskan yatakli kurutucuda kurutulur. Kurutulan bu karisim diger dolgu maddeleri ile birlikte belirli bir homojenlige gelinceye kadar karistirilir. Karisimin son 3-5 dakikasinda kaydirici eklenir. Elde edilen final karisimdan örnekler alinir ve laboratuvara gönderilir. Laboratuvar sonucuna göre tablet basimina yada istenilen farmasötik form için asamalara geçilebilir. Age Granulation; In the wet granulation method, high speed fluidized bed granulation, spray drying and extrusion pelletizing methods are used. Mourning In granulation, the active ingredient and the binder (solution) are mixed for a certain period of time. sieved and dried in a fluidized bed dryer. This dried mixture is the other filling. It is mixed with the ingredients until it reaches a certain homogeneity. My wife's last 3-5 slider is added in minutes. Samples are taken from the final mixture obtained and sent to the laboratory. sent. According to the results of the laboratory, for tablet compression or for the desired pharmaceutical form. stages can be passed.
Yas granülasyon yöntemleri: 1. Yas granülasyon yöntemi (Klasik yöntem) 2. Akiskan yatak yöntemiyle granülasyon 3. Spray-Drying (püskürterek kurutma) yöntemi ile granülasyon 4. Mikrogranülasyon yöntemi . Ekstrüsyon-Spheronizasyon yöntemi 6. Yüksek hiza sahip karistiricilarla granüle hazirlama yöntemi Yas granülasyon islemi su sirayi izlemektedir: - Etken maddenin (gerekli görülür ise) ögütülmesi, - Toz maddelerle karistirilmasi, - Baglayici ilavesiyle toz karisimin partiküllerinin kümelesmesinin saglanmasi, (Bu isleme granülasyon denir.) - Kümelesmis partiküllerin yas olarak elenmesi, - Elenmis toz karisiminin kurutulmasi kurutma islemde yaygin alarak akiskan yatakli kurutueular kullanilmasi, - Çift konik ya da V tipi karistiricilarda homojenize edilmesi karisima final ürün denir) - Tablet basimina yada istenilen farmasötik form için asamalara geçilmesidir. Age granulation methods: 1. Age granulation method (Classical method) 2. Granulation by fluidized bed method 3. Granulation by Spray-Drying method 4. Microgranulation method . Extrusion-Spheronization method 6. Method of preparing granules with high-level mixers The wet granulation process is as follows: - Grinding the active ingredient (if necessary), - Mixing with powder substances, - Ensuring the aggregation of the particles of the powder mixture with the addition of binder, The process is called granulation.) - Screening of agglomerated particles as wet, - Drying of the sifted powder mixture is common in the drying process using bed dryers, - Homogenizing in double conical or V type mixers the mixture is called the final product) - It is the transition to tablet pressing or the stages for the desired pharmaceutical form.
Kuru Granülasyon: Kuru granülasyon yönteminde, ön kompresyon ve silindirler arasi sikistirma yöntemleri kullanilmaktadir. Kuru granülasyonda genellikle formüldeki kaydiricinin l/3”ü diger toz karisimlarina karistirilir. Bunun nedeni tozlarin silindirlere yapismasini engeller. Kaydiricinin geri kalani kuru granülasyondan sonra karisima eklenir ve 3-5 dakika karistirilir. Karisim sonrasinda olusan final karisimdan örnekler alinir ve çesitli testler için laboratuvara gönderilir. Laboratuvar sonucuna göre tablet basimina yada istenilen farrnasötik form için uygun asamalara geçilebilir. Dry Granulation: In the dry granulation method, pre-compression and inter-roll compression methods are used. In dry granulation, it is usually 1/3 of the lubricant is mixed with other powder mixtures. This is because dust gets into the cylinders. prevents it from sticking. The remainder of the lubricant is added to the mix after dry granulation. and stirred for 3-5 minutes. Samples are taken from the final mixture formed after the mixture and It is sent to the laboratory for various tests. According to the laboratory results, tablet compression or Appropriate steps can be passed for the desired pharmaceutical form.
Oral kullanilmak üzere hazirlanan tablet/ ler bir veya daha fazla kaplama içerebilir. Tablet(s) prepared for oral use may contain one or more coatings.
Kaplanmis tabletler; etken maddeyi genellikle çekirdek kisminda, kismen çekirdekte ve kismende kaplamada veya yalniz kaplamada ihtiva eden formüller seklinde hazirlanir. coated tablets; The active ingredient is usually in the core, partially in the core and It is prepared in the form of formulas containing partially coating or only coating.
Kaplama maddeleri fizyolojik bakimdan zararsiz olmali ve etken madde ile geçimsiz olmamalidir. Coating materials must be physiologically harmless and incompatible with the active substance. should not be.
Kaplama tipleri ; seker kaplama, film kaplama ve bagirsakta çözünen (enterik) kaplama olarak sayilabilir. Coating types ; sugar coating, film coating and intestinal soluble (enteric) coating can be counted as
Seker kaplamali tabletler, sekerden meydana gelen bir kaplamaya sahip olan sikistirilmis tabletlerdir. Söz konusu kaplama renklendirilmis olabilir ve rahatsiz edici bir tada veya kokuya sahip olan etkin maddelerin kaplanmasi ve oksidasyona karsi hassasiyet gösteren malzemelerin korunmasi bakimindan son derece faydalidir. Sugar-coated tablets are compressed tablets having a coating consisting of sugar. are tablets. The coating may be colored and may have an offensive taste or coating of active substances with odor and sensitive to oxidation It is extremely useful in terms of protecting materials.
Film kaplamali tabletler, suda çözünebilen bir malzeme kullanilarak uygulanan ince bir katman veya filmle kaplanmis, sikistirilmis tabletlerdir. Bu dogrultuda, film Olusturucu özelliklere sahip olan bir dizi polimerik malzeme kullanilabilir. Film kaplamalar, seker kaplamalar ile ayni genel özelliklere sahip olmakla beraber kaplama islemi için gerekli süreyi önemli ölçüde azaltmak gibi önemli ek bir avantaji beraberinde getirir. Film-coated tablets are a thin film applied using a water-soluble material. Compressed tablets coated with a layer or film. In line with this, the movie Maker A range of polymeric materials can be used with properties Film coatings, sugar Although it has the same general properties as the coatings, it is necessary for the coating process. It brings with it the important additional advantage of significantly reducing the time.
Kaplamanin Amaçlari ; - Etkeii maddenin istenmeyen kokusunun ve tadinin maskelenmesi - Tabletin estetik görüntüsünün düzeltilmesi - Çok az boyar madde ile renkli tabletlerin elde edilmesi - Tabletin hasta tarafindan kolay yutulabilirliginin arttirilmasi ° Üretim, ambalajlama ve tasima sirasinda mekanik dayanikliligin artmasi - Etken maddenin sindirim salgilarina karsi korunmasi ° Yan etkilerden, örnegin mide iritasyonundan kaçinilmasi - Ilacin taninmasinin kolaylastirilmasi, dolayisiyla ilaç kullaniminda güvenligin artmasi - Etken maddenin kararliliginin arttirilmasi - Kontrollü salim karakteristiklerinin düzenlenebilmesi olarak sayilabilir. Purposes of Coating; - Masking off the offending odor and taste of the active ingredient - Correction of the aesthetic appearance of the tablet - Obtaining colored tablets with very little dyestuff - Increasing the easy swallowing of the tablet by the patient ° Increased mechanical strength during production, packaging and transportation - Protection of the active substance against digestive secretions ° Avoidance of side effects, eg stomach irritation - Facilitating the recognition of the drug, thus ensuring safety in drug use. increase - Increasing the stability of the active ingredient - It can be counted as being able to regulate the controlled release characteristics.
Bulustaki farmasötik fomiülasyoii/lar bir veya daha fazla tabaka içerebilir. Yeterli terapötik etkiyi saglamak ve yan etkileri minimuma indirniek amaciyla ilacin saliminin kontrolünü saglamak için tabaka/lar degistirilmis, modifiye, kontrollü, uzatilmis, sürekli, hemen veya geciktirilmis saliirili farmasötik dozaj formlarinin bir veya daha fazlasi ile formüle edilebilir. The pharmaceutical formulation(s) of the invention may contain one or more layers. Sufficient To ensure the therapeutic effect and to minimize the side effects, the release of the drug should be reduced. layer/s are changed, modified, controlled, extended, continuous, with one or more of the immediate or delayed release pharmaceutical dosage forms can be formulated.
Farmakokinetik özellikleri, kullaniin beklentilerine uygun olmayan, örnegin yarilanma ömrü kisa olan, istenmeyen etkileri ortaya çikaracak biçimde hizli/yüksek doruk konsantrasyona ulasan, çesitli nedenlerden biyoyararlanimi iyi olinayan v.b. ilaçlar için farmasötik biçimleri degistirilerek, mide barsak kanalinda serbestleiime paternleri amaca daha uygun hale getirilmis preparatlar gelistirilmektedir. Bunlar çoklukla degistirilmis, kontrollü, yavaslatilmis ve uzatilmis salinimli formülasyonlar olarak anilmaktadir. Its pharmacokinetic properties are not in accordance with the user's expectations, for example half-life. short-lived, rapid/high peak with undesirable effects concentration, which is not well bioavailable for various reasons, etc. for drugs By changing the pharmaceutical forms, the release patterns in the gastrointestinal tract are aimed at the purpose. More optimized preparations are being developed. These have been changed many times, They are referred to as controlled, slowed and extended release formulations.
Degistirilmis salinimli formülasyonlarin bilesimleri islevleri açisindan önem tasir. The compositions of modified release formulations are important for their function.
Degistirilmis salinimli ilaç formülasyonlari, daha pahali olabilmelerine ragmen, hastanin tedaviye uyumunun tedavi basarisinda önemli oldugu kisa yarilanma ömürlü, doruk konsantrasyona hizli ulasan, farmakokinetigi degiskenlik gösteren ilaçlar için daha kullanislidir ve son tahlilde tedavi maliyetini azaltirlar. Degistirilmis salim sistemleri transdermal sistemler ve oral sistemler olarak siniIlandirilir. Geciktirilmis salim sistemlerinde etkin maddenin sistemden salimi belli bir bölgede olmaktadir. Genellikle enterik kapli tabletler için kullanilir. Modified-release drug formulations, although they may be more expensive, short half-life, peak, in which adherence to treatment is important for treatment success For drugs that reach concentration rapidly, with varying pharmacokinetics, They are useful and ultimately reduce the cost of treatment. Modified release systems They are classified as transdermal systems and oral systems. delayed release In systems, the release of the active substance from the system occurs in a certain region. Generally It is used for enteric coated tablets.
Enterik kaplama formülasyonun stabilitesini arttirmak, asit kaynakli bozunmalari önleinek için kullanilan madde veya madde karisimlari olarak ifade edilir, Bu enterik kaplamalar ayrismaya baslamadan önce mide asidine direnç göstermekte ve ayni zamanda midenin alt kisminda veya ince bagirsagin üst kisminda yavas bir ilaç salinimini saglamaktadir. To increase the stability of the enteric coating formulation, to prevent acid-induced degradation. Expressed as substances or mixtures of substances used for these enteric coatings before it starts to decompose, it resists stomach acid and at the same time, it It provides a slow drug release in the upper part of the small intestine or in the upper part of the small intestine.
Kapsüller; tek dozda ilaç koninaya mahsus jelatin, selüloz esterleri, polivinil alkol Vb. maddelerden biriyle yapilmis kaplardir. Kapsüllere dozlar, kati ve yarikati maddeler, kapsülü eritmeyen sivi ilaçlar konabilir. Kapsüller genel olarak ikiye ayrilir; sert/iki parçali kapsüller ve yumusak kapsüller. capsules; gelatin, cellulose esters, polyvinyl alcohol etc. for single dose medicine cone. They are containers made of one of the materials. Doses, solid and partial substances into capsules, Liquid drugs that do not dissolve the capsule can be placed. Capsules are generally divided into two; rigid/two-piece capsules and soft capsules.
Sert kapsüller: kab ve kapak kismi olmak üzere iki parçadan ibarettir. Tadi aci, yutulmasi zor, havadan çabuk bozulan tozlar ile absorbsiyonu hizli olmasi istenen ilaçlarin kapsül içinde verilmesi öngörülür. Sert jelatin kapsüllerin esas maddesi makromoleküler bir protein olan yüksek degerli jelatinden ibarettir. Sert jelatin kapsüller jelatin, Arap zamki, boya ve su karisimindan özel teknikler ve özel makinelerle hazirlanir. Sert kapsüller daldirma (dipping) yöntemi ile hazirlanir. Bu yöntemin prensibi paslanmaz çelikten yapilmis çubuklarin eritilmis kapsül duvari çözeltisine batirilarak bu çubuklarin yüzeyinde kapsül duvari filminin olusturulmasidir. Jelatin, boyalar, koruyucu maddeler ve su , sert jelatin kapsül duvarini olusturan maddelerdir. Hard capsules consist of two parts: the container and the lid part. Bitter taste, swallowed capsules of difficult, air-perishable powders and drugs that are required to be rapidly absorbed. provided in. The main ingredient of hard gelatin capsules is a macromolecular It consists of high-value gelatin, which is a protein. Hard gelatin capsules gelatin, gum arabic, It is prepared from a mixture of paint and water with special techniques and special machines. hard capsules It is prepared by dipping method. The principle of this method is made of stainless steel on the surface of these rods by immersing them in the melted capsule wall solution. is the formation of the capsule wall film. Gelatin, dyes, preservatives and water, hard They are the substances that make up the gelatin capsule wall.
Sert kapsüllere toz, granül, pellet, tablet, sivi, ve yari kati sekiller doldurulabilir. Hard capsules can be filled in powder, granule, pellet, tablet, liquid, and semi-solid forms.
Kapsüllere doldurulan her türlü formülasyon için iki temel gereklilik söz konudurKapsüle, formülasyon dogru dozda doldurulmalidir ve etkin madde hastanin tedavisi için kapsülden yeterli miktarda salinmalidir. Sert jelatin kapsül formülasyonlarinin hazirlanmasi amaciyla etkin madde, dolgu maddeleri, akis özelliklerini düzelten maddeler, glidaiitlar, sürtünmeyi önleyiciler, lubrikantlar, dagiticilar, yüzey etkin maddeleri kullanilir. There are two basic requirements for any formulation filled into capsules. The formulation must be filled in the correct dose and the active substance is released from the capsule for the treatment of the patient. should be released in sufficient quantity. For the preparation of hard gelatin capsule formulations active ingredient, fillers, flow improvers, glidaides, friction inhibitors, lubricants, dispersants, surfactants are used.
Yumusak kapsüller: jelatin gliserin, sorbitol, arap zamki ve su karisimlari ile hazirlanan tek parçadan ibaret yuvarlak, elips ve tüp biçiminde kapsüllerdir. Gerekli olan maddeler konulduktan sonra açilmamak üzere kapatilirlar. Yumusak kapsüller,sivi bir içerigin jelatin kapsül duvari ile çevrelenmesi ile hazirlanir. Sert kapsüllere göre daha esnektirler. Soft capsules: single gelatin prepared with mixtures of glycerin, sorbitol, gum arabic and water. They are round, elliptical and tube-shaped capsules consisting of pieces. Required items After being placed, they are closed to not open. Soft capsules, gelatin of a liquid content It is prepared by enclosing it with the capsule wall. They are more flexible than hard capsules.
Yumusak kapsüller yuvarlak, oval, oblong (dikdörtgen çubuk) veya tüp seklinde olabilirler. Tek parçadan olusurlar. Yumusak jelatin kapsüllere genelde çözelti veya süspansiyon seklindeki sivi ilaç sekilleri doldurulur. Ancak yari kati ve tozlar da doldurulabilir. Yumusak kapsüllerin imalati, çözünmeyen maddeler, dozu düsük etkin maddeler, yüksek aktivite gösteren bilesikler, oksijene duyarli maddeler, tadi kötü maddeler için uygundur. Yumusak jelatin kapsüllerin üretiminde, kapsül duvarinin hazirlanmasi, materyalin doldurulmasi ve kapsülün kapatilmasi birbirini takip eden bir dizi islemden olusur. Soft capsules are round, oval, oblong (oblong stick) or tubular they may be. They consist of one piece. Soft gelatin capsules are usually included in solution or Liquid drug forms in suspension form are filled. However, semi-solids and powders are also can be filled. Production of soft capsules, insoluble substances, low-dose active substances, highly active compounds, oxygen sensitive substances, bad taste suitable for materials. In the production of soft gelatin capsules, the capsule wall a successive sequence of preparation, filling of the material and closure of the capsule. consists of the name.
Suruplar, sakkaroz veya diger sekerlerin yüksek derisimdeki çözeltilerinin içindeki etkin madde ve yardimci maddelerin çesitli yöntemlerle çözünmesi ile olusmus sivi ilaç sekilleridir. Sadece % 64 oraninda sakkarozun suda çözünmesi ile hazirlanmis suruplara Basit Surup (Sirupus Simplex) denir. Suruplar, USP 24°e göre % 85 a/h de seker içerirler. Syrups are active in high skin solutions of sucrose or other sugars. liquid medicine formed by the dissolution of substances and auxiliary substances by various methods are shapes. Syrups prepared by dissolving only 64% sucrose in water It is called Simple Surup (Sirupus Simplex). The syrups contain 85% w/v sugar according to USP 24°.
Suruplara seker ve diger tatlandiricilarin yani sira kristallenmeyi engellemek, çözünürlügü ve tadi degistirmek için sorbitol veya gliserin ve koku vermek için aromatik maddeler ilave Suruplarin hazirlama yöntemleri: - Sicakta veya sogukta basit çözündürme yoluyla hazirlananlar - Ekstre ve tentürlerle hazirlanan suruplar - Maserasyon ve dijestiyon yöntemi ile hazirlananlar - Meyva usareleri ile hazirlanan suruplar - Perkolasyon yolu ile hazirlananlar Tekrar çözündürme yöntemi ile hazirlananlar olarak siralanabilir. In addition to sugar and other sweeteners, it is added to syrups to prevent crystallization, increase solubility. and adding sorbitol or glycerin to alter the taste and aromatic substances to impart flavor Preparation methods of syrups: - Prepared by simple thawing in hot or cold - Syrups prepared with extracts and tinctures - Prepared by maceration and digestion method - Syrups prepared with fruit juices - Prepared by percolation Resolution method can be listed as those prepared with.
Mevcut bulustaki oral kullanim için hazirlanan farmasötik formülasyon; farmasötik olarak kabul edilebilir uygun etken maddeler yaninda baglayici madde, dagitici madde, dolgu maddesi, tamponlayici ajan, yüzey aktif madde, lubrikant, glidant, seyreltici madde, koruyucu madde, aroma ajani, tatlandirici madde, Viskozite arttirici madde, köpük önleyici ajan, çözünürlük arttirici ajan, antistatik ajan, islatici madde, pH ayarlayici madde, renklendirici madde, kaplama maddesi, çözücü, yumusatici madde, emülgatör, tasiyici, geçirgenlestirici madde, antioksidan, selat yapici ajan, alkalilestirici ajan, fotokoruyucu ajan, kivam arttirici madde, izotoni ayarlayici ajan, jel yapici ajan, mikrobiyal koruyucu madde, sertlestirici ajan, sivag, saliin kontrol edici ajan, plastifiyan, antiadherent, film yapici ajan, opaklastirici madde, nemlendirici madde, granülasyon çözücüsü, süspansiyon ajani ve stabilizörün de dahil oldugu gruptan seçilen bir veya daha fazla yardimci madde içerebilen bir bilesimi tanimlar. The pharmaceutical formulation prepared for oral use in the present invention; pharmaceutically Acceptable suitable active ingredients as well as binder, dispersant, filler agent, buffering agent, surfactant, lubricant, glidant, diluent, preservative, flavoring agent, sweetening agent, viscosity increasing agent, antifoam agent, solubilizing agent, antistatic agent, wetting agent, pH adjusting agent, coloring agent, coating agent, solvent, softening agent, emulsifier, carrier, permeabilizing agent, antioxidant, chelating agent, alkalizing agent, photoprotective agent, thickening agent, isotonia adjusting agent, gelling agent, microbial preservative substance, curing agent, sivag, saline controlling agent, plasticizer, antiadherent, film Builder agent, opacifying agent, wetting agent, granulation solvent, suspension one or more excipients selected from the group including the agent and stabilizer Defines a composition that can contain
Bulusta “baglayici madde” terimi; içerikteki maddeleri bir arada tutmak, tablet, pellet veya granüllerin gerekli olan mekanik güçte formüle edilmesini saglamak ve düsük aktif dozaj birimlerine hacim vermek için kullanilan madde veya madde karisimlari olarak ifade edilmektedir. Baglayici madde olarak; prejelatinize misir nisastasi, prejelatinize nisasta, hidroksi propil nisasta, jelatin, mikrokristalin selüloz, selüloz, zamklar, poliVinil pirolidon, polimetakrilatlar, sodyum karboksi metil selüloz, nisasta, parafinler, stearik asit, zamklar, metil selüloz, etil selüloz, polietilenglikol, magnezyum alüminyum silikat, karboksi metilselüloz, hidroksi propilselüloz, hidroksi etilselüloz, propilen glikol, polioksietilen- polipropilen kopolimeri, polietilen ester, polietilen sorbitan ester, polietilen oksit, polisakkaritler, polaksamerler, aljinik asitler, kolajen, albumin, krospovidon, povidon, kopovidon, maltodekstrin, hipromelloz veya bunlarin karisimlari kullanilabilir. The term "binding agent" in the invention; keeping the ingredients together, tablets, pellets or ensuring that the granules are formulated with the required mechanical strength and low active dosage. expressed as substances or mixtures of substances used to give volume to units of is being done. As a binding agent; pregelatinized corn starch, pregelatinized starch, hydroxypropyl starch, gelatin, microcrystalline cellulose, cellulose, gums, polyvinyl pyrrolidone, polymethacrylates, sodium carboxymethyl cellulose, starch, paraffins, stearic acid, gums, methyl cellulose, ethyl cellulose, polyethyleneglycol, magnesium aluminum silicate, carboxy methylcellulose, hydroxy propylcellulose, hydroxy ethylcellulose, propylene glycol, polyoxyethylene- polypropylene copolymer, polyethylene ester, polyethylene sorbitan ester, polyethylene oxide, polysaccharides, polaxamers, alginic acids, collagen, albumin, crospovidone, povidone, Copovidone, maltodextrin, hypromellose or mixtures of these can be used.
Bulusta “dagitici madde” terimi, dozaj formunun su içinde kolay ve hizli bir sekilde dagilmasini saglayan maddeler olarak ifade edilmektedir. Dagitici madde olarak; agar agar, kalsiyum karbonat, sodyum karbonat, aljinik asit, patates nisastasi, misir nisastasi, bugday nisastasi, prejelatinize nisasta, sodyum nisasta glikolat gibi nisastalar, mikrokristalin selüloz, çapraz-bagli polivinil pirolidon, sodyum aljinat, hidroksipropil selüloz, çapraz bagli hidroksipropil selüloz, kroskarmelloz sodyum, kil, iyon degistirici reçine, krospovidon, ksilitol, D-sorbitol, D-mannitol, laktoz, sükroz, üre, yüksek molekül agirlikli polimerler, povidon, aljinik asit, ksantan zamki, kolloidal silikon dioksit veya bunlarin karisimlari kullanilabilir. In the invention, the term "dispersant" means that the dosage form can be easily and quickly dissolved in water. It is expressed as substances that allow it to disperse. As a dispersant; agar agar, calcium carbonate, sodium carbonate, alginic acid, potato starch, corn starch, wheat Starches such as starch, pregelatinized starch, sodium starch glycolate, microcrystalline cellulose, cross-linked polyvinyl pyrrolidone, sodium alginate, hydroxypropyl cellulose, cross bound hydroxypropyl cellulose, croscarmellose sodium, clay, ion exchange resin, crospovidone, xylitol, D-sorbitol, D-mannitol, lactose, sucrose, urea, high molecular weight polymers, povidone, alginic acid, xanthan gum, colloidal silicon dioxide or their mixes can be used.
Bulusta “dolgu maddesi” terimi; tablet ya da kapsüllerin üretim için pratik, hasta kullanimina uygun büyüklükte olmasi için kullanilan madde veya madde karisimlari olarak ifade edilmektedir. Dolgu maddesi olarak; talk, laktoz, sukroz, dekstrin, mannitol, laktilol, laktitol, ksilitol, sorbitol, izomalt, mikrokristalin selüloz, toz selüloz, dekstroz, dekstrat, prejelatinize nisasta, modifiye nisasta, misir nisastasi, laktoz anhidröz, laktoz monohidrat, dibazik kalsiyum fosfat, silisik asit, kaolin, hidroksi propil metilselüloz, tribazik kalsiyum fosfat, polihidrik alkoller veya selüloz eterleri, kalsiyum hidrojen fosfat dihidrat, kalsiyum sülfat trihidrat, selüloz kalsiyum sülfat, kalsiyum sülfat dihidrat, maltodekstrin, kalsiyum karbonat, kaolin, sodyum hidroksit veya bunlarin karisimlari kullanilabilir. The term "filler" in the invention; practical, patient for the production of tablets or capsules as a substance or a mixture of substances used to be in a suitable size for its use is expressed. As a filler; talc, lactose, sucrose, dextrin, mannitol, lactilol, lactitol, xylitol, sorbitol, isomalt, microcrystalline cellulose, powdered cellulose, dextrose, dextrate, pregelatinized starch, modified starch, corn starch, lactose anhydrous, lactose monohydrate, dibasic calcium phosphate, silicic acid, kaolin, hydroxy propyl methylcellulose, tribasic calcium phosphate, polyhydric alcohols or cellulose ethers, calcium hydrogen phosphate dihydrate, calcium sulfate trihydrate, cellulose calcium sulfate, calcium sulfate dihydrate, maltodextrin, calcium carbonate, kaolin, sodium hydroxide or their mixtures can be used.
Bulusta “tamponlayici ajan” terimi, kompozisyonun asitlik ve bazligini düzenleyen maddeler olarak ifade edilmektedir. Tamponlayici ajan olarak; sitrik asit anhidrus, sodyum sitrat dihidrat, sodyum fosfat, sodyuin dihidrojeii fosfat, potasyum sitrat, fosforik asit, amonyum hidroksit, sitrik asit, diizopropanolamin, sodyum karbonat, sodyum silikat, disodyum ortofosfat, kalsiyum karbonat, magnezyum karbonat, magnezyum hidroksit, magnezyum alüminat, dietanol amin, sodyum aljinat, etilendiamin, meglümin, hidroklorik asit, laktik asit, sodyum sitrat, sodyum hidroksit, trietanolamin, trolamine, sodyum benzoat, sodyum hidrojen karbonat veya bunlarin karisimlari kullanilabilir. In the invention, the term "buffering agent" is used to regulate the acidity and basicity of the composition. referred to as items. As a buffering agent; citric acid anhydrous, sodium citrate dihydrate, sodium phosphate, sodium dihydrogei phosphate, potassium citrate, phosphoric acid, ammonium hydroxide, citric acid, diisopropanolamine, sodium carbonate, sodium silicate, disodium orthophosphate, calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium aluminate, diethanol amine, sodium alginate, ethylenediamine, meglumine, hydrochloric acid, lactic acid, sodium citrate, sodium hydroxide, triethanolamine, trolamine, sodium benzoate, sodium hydrogen carbonate or their mixtures can be used.
Bulusta “yüzey aktif madde” terimi suda veya sulu bir çözeltide çözündügünde yüzey gerilimini etkileyen kimyasal bilesigi ifade etmektedir. Yüzey aktif madde olarak polisorbatlar, sodyumlauril sülfat, sodyumstearil fumarat, non-iyonik polioksietileii polioksipropilen ko-polimeri, hekzadesil trimetil amonyum bromür, alkil polietilen oksit, polokzainerler, oktil glukozid, yag asitlerinin seker esterleri ve gliseritleri, dodesil betain, dodesil diinetilamin oksit, polioksil stearat, sodyum stereat, polietilen glikoller, L-lösin, alkil benzen sülfonat, yag asitleri, kuaterner amonyum bilesikleri veya bunlarin karisimlari kullanilabilir. In the invention, the term "surfactant" is applied when dissolved in water or an aqueous solution. It refers to the chemical compound that affects the voltage. As a surfactant polysorbates, sodiumlauryl sulfate, sodium stearyl fumarate, non-ionic polyoxyethylene polyoxypropylene co-polymer, hexadecyl trimethyl ammonium bromide, alkyl polyethylene oxide, poloxainers, octyl glucoside, sugar esters and glycerides of fatty acids, dodecyl betaine, dodecyl diethylamine oxide, polyoxyl stearate, sodium stearate, polyethylene glycols, L-leucine, alkyl benzene sulfonate, fatty acids, quaternary ammonium compounds or mixtures thereof can be used.
Bulusta “lubrikant” sürtünmeyi azaltan veya engelleyen bir toz karisiminin akis özelliklerini iyilestiren ajan veya ajan karisimlari olarak ifade edilmektedir. Lubrikant olarak; talk, kalsiyum stearat, magnezyum stearat, alüminyum stearat, polietilen glikol, tristearin, stearik asit, sodyum lauril sülfat, magnezyum lauril sülfat, kolloidal silikon dioksit, stearik asit, sodyum stearil fumarat, polioksietilen glikol, oleik asit, tripalmitil, potasyum oleat, hidrojene bitkisel yaglar, lösin, alanin, glisin, kaprilik asit, gliseril behenat, gliseril palmitostearat, sodyum benzoat, sodyum asetat, fumarik asit, çinko stearat, çinko oleat, çinko palmitat, parafinler, yag alkolleri veya bunlarin karisimlari kullanilabilir. "Lubricant" in the invention is the flow of a powder mixture that reduces or inhibits friction. It is expressed as agent or agent mixtures that improve its properties. lubricant aspect; talc, calcium stearate, magnesium stearate, aluminum stearate, polyethylene glycol, tristearin, stearic acid, sodium lauryl sulfate, magnesium lauryl sulfate, colloidal silicon dioxide, stearic acid, sodium stearyl fumarate, polyoxyethylene glycol, oleic acid, tripalmityl, potassium oleate, hydrogenated vegetable oils, leucine, alanine, glycine, caprylic acid, glyceryl behenate, glyceryl palmitostearate, sodium benzoate, sodium acetate, fumaric acid, zinc stearate, zinc oleate, zinc palmitate, paraffins, fatty alcohols or their mixtures can be used.
Bulusta “glidant” terimi; tablet basimi aninda matris bosluguna materyalin akisini kolaylastiran ekstra küçük partiküllü, dansitesi düsük madde olarak ifade edilmektedir. The term "glidant" in the invention; Tablet pressing immediately allows the flow of material into the matrix space. It is expressed as a substance with extra small particles and low density that facilitates it.
Glidant olarak; talk, magnezyum stearat, hidrojene nebati yag, kalsiyum stearat, stearik asit, kolloidal silikon dioksit, sodyum stearilfumarat, polioksietilenglikol, lösin, sodyum benzoat, sodyum kloiür, sodyum asetat, sodyum fumarat, silika, kolloidal anhidrus silika, polietilenglikol, selüloz türevleri, nisasta veya bunlarin karisimlari kullanilabilir. As a glidant; talc, magnesium stearate, hydrogenated vegetable oil, calcium stearate, stearic acid, colloidal silicon dioxide, sodium stearylfumate, polyoxyethyleneglycol, leucine, sodium benzoate, sodium chloride, sodium acetate, sodium fumarate, silica, colloidal anhydrous silica, polyethyleneglycol, cellulose derivatives, starch or their mixtures can be used.
Bulusta “seyreltici madde” terimi; tablet ya da kapsüllerin üretim için pratik, hasta kullanimina uygun büyüklükte olmasi için kullanilan madde veya madde karisimlari olarak ifade edilmektedir. Seyreltici madde olarak; laktoz, maltoz, sukroz, dekstrin, mannitol, laktilol, ksilitol, sorbitol, izomalt, mikrokristalin selüloz, dekstroz, dekstrat, prejelatinize nisasta, modifiye nisasta, misir nisastasi, laktoz anhidröz, laktoz monohidrat, dibazik kalsiyum fosfat, hidroksi propil metilselüloz, tribazik kalsiyum fosfat, polihidrik alkoller veya selüloz eterleri, kalsiyum hidrojen fosfat dihidrat, kalsiyum sülfat trihidrat, kalsiyum sülfat dihidrat, maltodekstrin, kalsiyum karbonat, kaolin, sodyum hidroksit veya bunlarin karisimlari kullanilabilir. The term "diluent" in the invention; practical, patient for the production of tablets or capsules as a substance or a mixture of substances used to be in a suitable size for its use is expressed. As a diluent; lactose, maltose, sucrose, dextrin, mannitol, lactylol, xylitol, sorbitol, isomalt, microcrystalline cellulose, dextrose, dextrate, pregelatinized starch, modified starch, corn starch, lactose anhydrous, lactose monohydrate, dibasic calcium phosphate, hydroxy propyl methylcellulose, tribasic calcium phosphate, polyhydric alcohols or cellulose ethers, calcium hydrogen phosphate dihydrate, calcium sulfate trihydrate, calcium sulfate dihydrate, maltodextrin, calcium carbonate, kaolin, sodium hydroxide or their mixes can be used.
Bulusta “koruyucu madde” terimi; su ve suda çözünen, yag ve yagda çözünen maddelerin mikroorganizmalara karsi korunmasini saglayan maddeler olarak ifade edilmektedir. The term "preservative" in the invention; water and water-soluble, oil and fat-soluble substances It is expressed as substances that provide protection against microorganisms.
Koruyucu madde olarak 2-fenoksietanol, sodyuin benzoat, benzoik asit, benzil alkol, etilendiamintetraasetik asit, sodyum metil parahidroksi beiizoat, sodyum propil para hidroksi benzoat, sorbik asit, potasyum sorbat, benzetonyum klorür, klorokresol, benzalkonyum klorür, butil paraben, metil paraben, propil paraben, etil paraben, butil hidroksi aiiisol (BHA), butil hidroksi tolueii (BHT), kalsiyum asetat, sitrik asit, disodyum edetat, gliserin, prOpil gallat, sodyum bisülfit, sodyum sitrat, sodyum metabisülfit, borik asit, sorbik asit, sodyum propionat, propilen glikol veya bunlarin karisimlari kullanilabilir. 2-phenoxyethanol, sodium benzoate, benzoic acid, benzyl alcohol as preservatives, ethylenediaminetetraacetic acid, sodium methyl parahydroxy beiizoate, sodium propyl para hydroxy benzoate, sorbic acid, potassium sorbate, benzetonium chloride, chlorocresol, benzalkonium chloride, butyl paraben, methyl paraben, propyl paraben, ethyl paraben, butyl hydroxy aiiisol (BHA), butyl hydroxy tolueii (BHT), calcium acetate, citric acid, disodium edetate, glycerin, prOpil gallate, sodium bisulfite, sodium citrate, sodium metabisulfite, boric acid, sorbic acid, sodium propionate, propylene glycol or their mixtures can be used.
Bulusta “aroma ajani” terimi, karisima aroma katmak için kullanilan maddeler olarak ifade edilmektedir. Aroma ajani olarak; dogal aroina yaglari (nane yagi, keklik üzümü yagi, maydanoz yagi, portakal yagi, üzüm, turunç, greyfurt, limon yagi, Vb.), portakal aromasi, muz aromasi, seftali aromasi, greyfurt aromasi, limon aromasi, elma aromasi, çilek aromasi, vanilya aromasi, nane aromasi, tutti-furitti aromasi, frambuaz aromasi, mentol, mentan, anetol, tarçin, metil salisilat, okaliptal, adaçayi, bögürtlen, sitrus meyvalari veya bunlarin karisimlari kullanilabilir. In the invention, the term "flavoring agent" is defined as substances used to add flavoring to the mixture. is being done. As a flavoring agent; natural essential oils (peppermint oil, wintergreen oil, parsley oil, orange oil, grape, citrus, grapefruit, lemon oil, etc.), orange flavor, banana flavor, peach flavor, grapefruit flavor, lemon flavor, apple flavor, strawberry flavor, vanilla flavor, mint flavor, tutti-furitti flavor, raspberry flavor, menthol, menthane, anethole, cinnamon, methyl salicylate, eucalyptal, sage, blackberry, citrus fruits or mixtures of these can be used.
Bulusta “tatlandirici madde” olarak; sodyum sakkarin, sakkaroz, D-glukoz, galaktoz, ksiloz, maltoz, maltodekstrin, maltol, eritritol, laktitol, izomalt, izoinaltol, misir surubu, D- triptofan, glisirizik asit, monoamonyum glisirrizinat, fruktoz, maltitol, dekstroz, sükroz, ksilitol, sorbitol, mannitol, laktoz, aspartam, asesülfam potasyum, neohesperidin dihidrokalkon, sükraloz, sodyum siklamat veya bunlarin karisimlari kullanilabilir. As a "flavoring agent" in the invention; sodium saccharin, sucrose, D-glucose, galactose, xylose, maltose, maltodextrin, maltol, erythritol, lactitol, isomalt, isoinaltol, corn syrup, D- tryptophan, glycyrrhizic acid, monoammonium glycyrrhizinate, fructose, maltitol, dextrose, sucrose, xylitol, sorbitol, mannitol, lactose, aspartame, acesulfame potassium, neohesperidin dihydrochalcone, sucralose, sodium cyclamate or their mixtures can be used.
Bulusta “viskozite arttirici madde” teriini, sivinin kalinligini arttirarak yavas akmasini saglayan bir ajan veya ajan karisimlari olarak ifade edilmektedir. Viskozite arttirici madde olarak; ksantan zamki, guar zamki, acacia, povidon, aljinik asit, etilselüloz, jelatin, hidroksietil selüloz, hidroksipropil selüloz, setil alkol, polivinil pirolidon, hidroksi propil metil selüloz, polidekstroz, karragenan, metil selüloz, sukroz, sorbitol, ksilitol, hidroksipropil metilselüloz, polivinil alkol, ketearil alkol, kolloidal silikon dioksit veya bunlarin karisiinlari kullanilabilir. In the invention, the term “viscosity increasing agent” is used to increase the thickness of the liquid and to make it flow slowly. It is expressed as an agent or agent mixtures that provide Viscosity increasing agent aspect; xanthan gum, guar gum, acacia, povidone, alginic acid, ethylcellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, cetyl alcohol, polyvinyl pyrrolidone, hydroxy propyl methyl cellulose, polydextrose, carrageenan, methyl cellulose, sucrose, sorbitol, xylitol, hydroxypropyl methylcellulose, polyvinyl alcohol, ketaryl alcohol, colloidal silicon dioxide or mixtures of these can be used.
Bulusta “köpük önleyici aj an” terimi ürün saklanirken köpürme reaksiyonunun baslamasini engelleyerek ürünü mevcut sistemde bulunan suya karsi stabilize eden maddeler olarak ifade edilmektedir. Köpük önleyici ajan olarak; siinetikon emülsiyon, dimetilsiloksan, silikon yagi, monosodyum karbonat, susuz trimagnezyum disitrat veya bunlarin karisimlari kullanilabilir. Köpük önleyici ajan dogrudan efervesan granüle veya dis fazda tabletin diger eksipiyanlarina toz halde karistirilarak veya hem efervesan granüle hem de tabletin eksipiyan karisimina paylastirilarak ilave edilebilir. In the invention, the term "antifoaming agent" refers to the initiation of the foaming reaction while the product is stored. as substances that stabilize the product against the water in the existing system by preventing is expressed. As antifoaming agent; sinethicone emulsion, dimethylsiloxane, silicone oil, monosodium carbonate, anhydrous trimagnesium dicitrate or mixtures thereof can be used. Antifoaming agent directly into effervescent granulated or external phase tablet It can be mixed with other excipients in powder form or made into both effervescent granules and tablets. It can be added to the excipient mixture by portioning.
Bulusta çözünürlük arttirici ajan olarak; sodyum kazeinat, polisorbat, metakrilikasit kopolimeri veya bunlarin karisimlari kullanilabilir. As a solubilizing agent in the invention; sodium caseinate, polysorbate, methacrylic acid copolymer or mixtures thereof can be used.
Bulusta “antistatik ajan” terimi; içerikteki statik elektrigi azaltan veya elimine etmek için kullanilan madde veya madde karisimlari olarak ifade edilmektedir. Bahsi geçen antistatik ajan olarak; uzun zincirli alifatik aminler ve amidler, kuarterner amonyum tuzlari, fosforik asit esterleri, polietilen glikol esterleri, polioller, mono ve digliserid, yag asit esterleri veya bunlarin karisimlari kullanilabilir. The term "antistatic agent" in the invention; to reduce or eliminate static electricity in the content It is expressed as the substance or substance mixture used. The aforementioned antistatic as an agent; long chain aliphatic amines and amides, quaternary ammonium salts, phosphoric acid esters, polyethylene glycol esters, polyols, mono and diglyceride, fatty acid esters or mixtures of these can be used.
Bulusta “islatici madde” terimi hidrofobik ilaçlarin dispersiyon ortaminda kolayca dagilmasina yardim etmek amaciyla kullanilan maddeler olarak ifade edilmektedir. lslatici madde olarak; sodyum lauril sülfat, sodyum doküsat, polisorbatlar, sorbitan monolaurat, 0kt0ksinol-9, nonoksinol-lO, poloksamerler, sodyum karboksimetil selüloz, bentonit, benzalkonyum klorür, tetradesiltrimetil amonyum bromür, setilpiridinyuin klorür, gliseril monostearat, makrogol setostearil eter, sorbitan tristearat, aluminyuiri magnezyum silikat veya bunlarin karisimlari kullanilabilir. In the invention, the term "wetting agent" is readily available in the dispersion medium of hydrophobic drugs. It is expressed as substances used to help dispersal. slacker as substance; sodium lauryl sulfate, sodium docusate, polysorbates, sorbitan monolaurate, 0kt0xinol-9, nonoxynol-10, poloxamers, sodium carboxymethyl cellulose, bentonite, benzalkonium chloride, tetradecyltrimethyl ammonium bromide, cetylpyridineyuin chloride, glyceryl monostearate, macrogol cetostearyl ether, sorbitan tristearate, aluminiumi magnesium silicate or mixtures of these can be used.
Bulusta “pH ayarlayici madde” terimi, kompozisyonun asitlik ve bazligini düzenleyen maddeler olarak ifade edilmektedir. pH ayarlayici madde olarak; sitrik asit anhidrus, sodyum sitrat dihidrat, sodyum fosfat, sodyum dihidrojen fosfat, potasyum sitrat, fosforik asit, amonyum hidroksit, sitrik asit, diizopropanolamin, sodyum karbonat, sodyum silikat, disodyum ortofosfat, kalsiyum karbonat, magnezyum karbonat, magnezyum hidroksit, magnezyuin alüminat, dietanol amin, sodyum aljinat, etilendiamin, meglümin, hidroklorik asit, laktik asit, sodyum sitrat, sodyum hidroksit, sodyum klorür, trietanolamin, trolamine, sodyum benzoat, sodyum hidrojen karbonat veya bunlarin karisimlari kullanilabilir. In the invention, the term "pH adjusting agent" is used to regulate the acidity and basicity of the composition. referred to as items. As a pH adjusting agent; citric acid anhydrous, sodium citrate dihydrate, sodium phosphate, sodium dihydrogen phosphate, potassium citrate, phosphoric acid, ammonium hydroxide, citric acid, diisopropanolamine, sodium carbonate, sodium silicate, disodium orthophosphate, calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium aluminate, diethanol amine, sodium alginate, ethylenediamine, meglumine, hydrochloric acid, lactic acid, sodium citrate, sodium hydroxide, sodium chloride, triethanolamine, trolamine, sodium benzoate, sodium hydrogen carbonate or their mixtures can be used.
Bulusta “renklendirici madde” terimi hos bir görünüs veren ve iki formülasyon arasinda optik olarak ayirt edilme saglayan maddeler olarak ifade edilmektedir. Renklendirici madde olarak, bunlarla sinirli kalmamakla birlikte, sari demir oksit, kirmizi demir oksit gibi demir oksit pigmentleri, ß-karoten, kirmizi pancar tozu, klorofil, tartrazin, sari portakal, kinolin sarisi, eritrosin, titanyum dioksit pigmentleri, karamel, gün batimi sarisi veya bunlarin karisimlari kullanilabilir. In the invention, the term "coloring agent" is a pleasant-looking and intermediate between the two formulations. They are expressed as substances that provide optical discrimination. Colorant as substances, but not limited to, yellow iron oxide, red iron oxide such as iron oxide pigments, ß-carotene, red beet powder, chlorophyll, tartrazine, yellow orange, quinoline yellow, erythrosine, titanium dioxide pigments, caramel, sunset yellow or mixtures of these can be used.
Bulusta “kaplama maddesi” terimi formülasyon içerigini havadaki nem tarafindan bozunmaya karsi korumak ve tadi hos olmayan formlari yutma kolayligi saglamak için kullanilan madde veya madde karisimlari olarak ifade edilmektedir. Kaplama maddesi olarak; metil selüloz, hidroksietilselüloz, hidroksibutilselüloz, hidroksipropilmetilselüloz, etil selüloz, hidroksimetil selüloz, hidroksipropilselüloz, karboksimetiletilselüloz, sodyum karboksimetil amilopektin, polivinil asetat ftalat, polioksietilen glikol, polivinil alkol(opadry çesitleri), polivinil asetal dietil aminoasetat, aminoalkil metakrilat kopolimer, metakrilik asit kopoliineri, hidroksipropil metil selüloz asetat, dioksi metil selüloz süksinat, karboksi metil etil selüloz, poliakrilik asitler, metakrilik asit kopolimerleri, metil akrilat, etilakrilat, metilmetakrilat, etilmetakrilat, akrilik ve metakrilik asit esterleri, hipromelloz, hipromelloz ftalat, hipromelloz asetat süksinat, hidroksimetil selüloz süksinat asetat, selüloz butirat ftalat, selüloz hidrojen ftalat, selüloz propiyanat ftalat, selüloz asetat ftalat, hidroksipropilmetilselüloz ftalat, selüloz asetat trimelitat, jelatin, selak, hint yagi, kitosan, aljinik asit, Irlanda yosunlari, galaktomanonlar, tragakant, Hint tutkali, arap zamki, guar zamki, ksantan zamki veya bunlarin karisimlari kullanilabilir. Çözücü olarak saflastirilmis su, etil alkol, metil alkol, isopropil alkol, butil alkol gibi alkoller, aseton, diaseton, polioller, polieterler, esterler, alkil ketonlar, metilen klorür, metil asetat, etil asetat, izopropil asetat, kastor yagi, etilen glikol monoetil eter, dietilen glikol monobutil eter, dietilen glikol inonoetil eter, diinetil sülfoksit, diinetil forrnamid, tetrahidroûiran veya bunlarin karisimlari kullanilabilir, Bulusta “yumusatici madde” terimi; cilt üzerinde ince bir film tabakasi olusturarak suyun uçmasina engel olan maddeler olarak ifade edilmektedir. Yumusatici madde olarak vazelin, kati vazelin, sivi parafin, sorbitol, gliserin, hidrokarbonlar, lanolin, mumlar, yag asitleri, setil alkol, oktildodekanol, kaprilik/ kaprik trigliserit, setil stearil alkol, kakao yagi, diizopropil adipat, gliserin, polihidrik alkoller ve polieter türevleri, polihidrik alkol esterleri, gliseril monooleat, gliseril stearat, linoleik asit, oleik asit, polipropilen glikol-lS stearil eter (PPG-15 stearil eter), polietilen glikol, polioksietilen glikol yagli alkol eterleri, polioksipropilen stearil eter, propilen glikol stearat, stearik asit, stearil alkol, fosfolipidler, lesitin, steoroller, kolesterol, kolesterol yag asidi esterleri ve amidleri, üre, gliseril monostearat, isopropil miristat, isopropil palmitat, ketostearil alkol, dimetikon, mineral yaglar, beyaz kati parafin, setearil alkol veya bunlarin karisimlari kullanilabilir. Ayrica hint yagi, Hindistan cevizi yagi, zeytinyagi ve bitkisel mumlar gibi bitkisel yumusatici ajanlar da kullanilabilir. In the invention, the term "coating agent" describes the formulation content by moisture in the air. to protect against degradation and to facilitate swallowing unpleasant-tasting forms. It is expressed as the substance or substance mixture used. Coating agent aspect; methyl cellulose, hydroxyethylcellulose, hydroxybutylcellulose, hydroxypropylmethylcellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropylcellulose, carboxymethylethylcellulose, sodium carboxymethyl amylopectin, polyvinyl acetate phthalate, polyoxyethylene glycol, polyvinyl alcohol (opadry varieties), polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymer, methacrylic acid copolyiner, hydroxypropyl methyl cellulose acetate, dioxy methyl cellulose succinate, carboxy methyl ethyl cellulose, polyacrylic acids, methacrylic acid copolymers, methyl acrylate, ethylacrylate, methylmethacrylate, ethylmethacrylate, acrylic and methacrylic acid esters, hypromellose, hypromellose phthalate, hypromellose acetate succinate, hydroxymethyl cellulose succinate acetate, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propyanate phthalate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, cellulose acetate trimellitate, gelatin, celak, castor oil, chitosan, alginic acid, carrageenan, galactomanones, tragacanth, castor oil, gum arabic, guar gum, xanthan gum or their mixtures can be used. Such as purified water, ethyl alcohol, methyl alcohol, isopropyl alcohol, butyl alcohol as a solvent. alcohols, acetone, diacetone, polyols, polyethers, esters, alkyl ketones, methylene chloride, methyl acetate, ethyl acetate, isopropyl acetate, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol inonoethyl ether, diethyl sulfoxide, diynethyl forrnamide, tetrahydroiran or mixtures thereof can be used, The term "softening agent" in the invention; water by forming a thin film on the skin It is expressed as substances that prevent it from flying. Vaseline as an emollient, solid petrolatum, liquid paraffin, sorbitol, glycerin, hydrocarbons, lanolin, waxes, fatty acids, cetyl alcohol, octyldodecanol, caprylic/capric triglyceride, cetyl stearyl alcohol, cocoa butter, diisopropyl adipate, glycerine, polyhydric alcohols and polyether derivatives, polyhydric alcohol esters, glyceryl monooleate, glyceryl stearate, linoleic acid, oleic acid, polypropylene glycol-1S stearyl ether (PPG-15 stearyl ether), polyethylene glycol, polyoxyethylene glycol fatty alcohol ethers, polyoxypropylene stearyl ether, propylene glycol stearate, stearic acid, stearyl alcohol, phospholipids, lecithin, steorols, cholesterol, cholesterol fatty acid esters and amides, urea, glyceryl monostearate, isopropyl myristate, isopropyl palmitate, ketostearyl alcohol, dimethicone, mineral oils, white solid paraffin, cetearyl alcohol or their mixtures can be used. Moreover herbal emollient such as castor oil, coconut oil, olive oil and vegetable waxes agents can also be used.
Bulusta “emülgatör” terimi, birbiri içerisinde karismayan iki SlVl faz arasinda homojen dagilimi saglayan maddeler olarak ifade edilmektedir. Emülgatör olarak polietilen glikol stearat, polisorbat, poligliseril oleat, polioksietilen lauril eter, etoksillenmis lanolin, stearil alkol, setostearil alkol, makrogol setostearil, gliseril monostearat, setil alkol, polioksietilen lauril alkol, polioksi etilen sorbitan monostearat, polioksietilen stearat, sorbitan inonostearat, propilen glikol stearat, alüminyum nisasta oktenilsuksinat, amonyuin hidroksit, beyaz bir balmumu, sentetik bir balmumu, karboiner, setearil alkol, siklometikon, digliseritler, dimetikon, disodyum monooleamido sülfosüksinat, pentaeritritol, gliseritler, gliseril monooleat, gliseril stearat, lanolin, magnezyum hidrojene stearat, mineral yag, monogliseridler, polietilen glikol, polietilen glikol distearat, polietilen glikol monosetil eter, polietilen glikol monostearat, polioksietilen glikol, polioksil setostearil eter, polioksil stearat, simetikon, sorbitan monolaurat, sorbitan monooleat, sorbitan monopalmitat, sorbitan palmitat, stearik asit, trietanolamin veya sodyum lauril sülfat veya bunlarin karisimlari kullanilabilir. In the invention, the term "emulsifier" means homogeneous between two LV1 phases that do not mix with each other. are expressed as substances that provide dispersion. Polyethylene glycol as emulsifier stearate, polysorbate, polyglyceryl oleate, polyoxyethylene lauryl ether, ethoxylated lanolin, stearyl alcohol, cetostearyl alcohol, macrogol cetostearyl, glyceryl monostearate, cetyl alcohol, polyoxyethylene lauryl alcohol, polyoxy ethylene sorbitan monostearate, polyoxyethylene stearate, sorbitan inonostearate, propylene glycol stearate, aluminum starch octenylsuccinate, ammonia hydroxide, a white wax, a synthetic wax, carboiner, cetearyl alcohol, cyclomethicone, diglycerides, dimethicone, disodium monooleamido sulfosuccinate, pentaerythritol, glycerides, glyceryl monooleate, glyceryl stearate, lanolin, hydrogenated magnesium stearate, mineral oil, monoglycerides, polyethylene glycol, polyethylene glycol distearate, polyethylene glycol monocetyl ether, polyethylene glycol monostearate, polyoxyethylene glycol, polyoxyl cetostearyl ether, polyoxyl stearate, simethicone, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan palmitate, stearic acid, triethanolamine or sodium lauryl sulfates or their mixtures can be used.
Bulusta “tasiyici” olarak propilen glikol, saflastirilmis su, hint yagi, diizopropil adipat, etoksilatli alkol, yagli alkol sitrat, gliserin, heksilen glikol, izopropil alkol, izopropil miristat, izopropil palmitat, mineral yag, fosforik asit, polietilen tereftalat glikol, polietilen glikol, polietilen glikol inonostearat, polioksil ketostearil eter, polioksipropileii stearil eter, polisorbat, oktildodekanol, propilen karbonat, doymus yag asidi trigliseritler, benzoik asit, etanol veya bunlarin karisimlari kullanilabilir. Propylene glycol, purified water, castor oil, diisopropyl adipate, ethoxylated alcohol, fatty alcohol citrate, glycerine, hexylene glycol, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, mineral oil, phosphoric acid, polyethylene terephthalate glycol, polyethylene glycol, polyethylene glycol inonostearate, polyoxyl ketostearyl ether, polyoxypropyleii stearyl ether, polysorbate, octyldodecanol, propylene carbonate, saturated fatty acid triglycerides, benzoic acid, ethanol or mixtures thereof may be used.
Bulusta “geçirgenlestiriei madde” terimi, tükürügüri penetrasyonunu kolaylastiran ve böylece tabletin daha iyi dagilmasina katkida bulunan bir hidrofil ag olusmasini saglayan maddeler olarak ifade edilmektedir. Geçirgenlestirici madde olarak Çökeltilmis silisler, maltodekstrinler, ß-siklodekstrinler veya bunlarin karisimlari kullanilabilir. In the invention, the term "permeable material" refers to a substance that facilitates salivary penetration and thus creating a hydrophilic network that contributes to better dispersion of the tablet. referred to as items. Precipitated silicas as permeation agent, maltodextrins, ß-cyclodextrins or mixtures thereof may be used.
Bulusta “antioksidan” terimi serbest radikallerin neden oldugu oksidasyonlari önleyen, serbest radikalleri yakalama ve stabilize etme yetenegine sahip maddeler olarak ifade edilmektedir. Antioksidan olarak; tokoferol (E Vitamini), askorbik asit (C Vitamini), A vitamini, K vitamini gibi Vitaminler, karotenoitler, karotenler (ömegim (i-karoten, ß- karoten, likopen, lutein, zeaksantin), mineraller (Se, Zn), butil hidroksi anisol (BHA), butil hidroksi toluen (BHT), etilgalat, propilgalat, dodesilgalat, taurin, organosülfür bilesikleri (allium, alil sülfit, indoller), düsük molekül agirlikli antioksidanlar (GSH-Px, ürik asit) veya bunlarin karisimlari kullanilabilir. In the invention, the term “antioxidant” prevents oxidation caused by free radicals, are substances that have the ability to capture and stabilize free radicals. is being done. As an antioxidant; tocopherol (Vitamin E), ascorbic acid (Vitamin C), A Vitamins such as vitamin K, carotenoids, carotenes (eg (i-carotene, ß- carotene, lycopene, lutein, zeaxanthin), minerals (Se, Zn), butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT), ethylgalate, propylgalate, dodecylgalate, taurine, organosulfur compounds (allium, allyl sulfide, indoles), low molecular weight antioxidants (GSH-Px, uric acid) or mixtures of these can be used.
Bulusta selat yapici ajan olarak EDTA (etilen diamin tetraasetik asit), disodyum EDTA (disodyum etilen diamin tetraasetik asit) veya kalsiyum EDTA (kalsiyum etilen diamin tetraasetik asit) veya bunlarin karisimlari kullanilabilir. EDTA (ethylene diamine tetraacetic acid), disodium EDTA as chelating agent in the invention (disodium ethylene diamine tetraacetic acid) or calcium EDTA (calcium ethylene diamine) tetraacetic acid) or mixtures thereof can be used.
Bulusta alkalilestirici ajan olarak; sodyum karbonat, sodyum hidrojen karbonat, sodyum hidroksit, sodyum silikat, primer aminler, sekonder aminler, tersiyer aminler, siklik aminler, kalsiyum gliserofosfat, kalsiyum glukonat, kalsiyum asetat, N,N, dibenziletilendiamin, dietanolamin, etilendiamin, meglümin, disodyum hidrojen ortofosfat, sodyum alüminat, kalsiyum karbonat, kalsiyum hidroksit, magnezyum karbonat, magnezyum hidroksit, magnezyum sülfat, monosodyum glutamat, polakrillin sodyum, sodyum aljinat, dibazik kalsiyum fosfat, tribazik kalsiyum fosfat, kalsiyum sülfat, magnezyum asetat, magnezyum silikat, magnezyum alüminat, magnezyum oksit veya bunlarin karisimlari kullanilabilir. As an alkalizing agent in the invention; sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, primary amines, secondary amines, tertiary amines, cyclic amines, calcium glycerophosphate, calcium gluconate, calcium acetate, N,N, dibenzylethylenediamine, diethanolamine, ethylenediamine, meglumine, disodium hydrogen orthophosphate, sodium aluminate, calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium sulfate, monosodium glutamate, polakrillin sodium, sodium alginate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, magnesium acetate, magnesium silicate, magnesium aluminate, magnesium oxide or mixtures of these can be used.
Bulusta fotokoruyucu ajan olarak; demir oksit türevleri, metal oksitler, titanyum oksit veya bunlarin karisimlari kullanilabilir. As a photoprotective agent in the invention; iron oxide derivatives, metal oxides, titanium oxide or mixtures of these can be used.
Bulusta “kivam arttirici madde” terimi formülasyonlarin çesitli basinç ve kuvvetlere karsi güçlendirilmesi için kullanilan maddeler olarak ifade edilmektedir. Kivam arttirici madde olarak; setil alkol, alüminyum stearat, dimetikon, setearil alkol, stearil alkol, arap zamki, kitre zamki, aljinat, karragen, ksantan zamki, guar zamki, setostearil alkol, setil esterlerin mumu, dekstrin, gliseril monostearat, hidroksipropil selüloz, kaolin, polietilen beyaz vazelin, propilen glikol stearat, nisasta, mum, beyaz mum, bentonit, balmumu, beyaz balmumu, sentetik balmumu, parafin, beyaz kati parafin, beyaz yumusak parafin, kati vazelin, pektin, karbomer, polivinilprolidon veya bunlarin karisimlari kullanilabilir. In the invention, the term "thickening agent" refers to the resistance of formulations to various pressures and forces. are expressed as substances used for strengthening. thickening agent aspect; cetyl alcohol, aluminum stearate, dimethicone, cetearyl alcohol, stearyl alcohol, gum arabic, gum tragacanth, alginate, carrageenan, xanthan gum, guar gum, cetostearyl alcohol, cetyl esters wax, dextrin, glyceryl monostearate, hydroxypropyl cellulose, kaolin, polyethylene white petrolatum, propylene glycol stearate, starch, wax, white wax, bentonite, beeswax, white beeswax, synthetic wax, paraffin, white solid paraffin, white soft paraffin, solid Vaseline, pectin, carbomer, polyvinylpyrrolidone or their mixtures can be used.
Bulusta “izotoni ayarlayici ajan” terimi, standart referans madde ile ayni osmotik basinca sahip maddeler olarak ifade edilmektedir. Bahsi geçen izotoni ayarlayici ajan olarak; sodyum klorür, mannitol, sorbitol, borik asit, potasyum nitrat, glukoz veya bunlarin karisimlari kullanilabilir. In the invention, the term "isotonia adjusting agent" means the same osmotic pressure as the standard reference substance. referred to as substances. As the aforementioned isotonia adjusting agent; sodium chloride, mannitol, sorbitol, boric acid, potassium nitrate, glucose or their mixes can be used.
Bulusta “jel yapici ajan” olarak karbopol, karbomer, hidroksi propilmetilselüloz, metilselüloz, sodyum karboksi metilselüloz, poliakrilat polimerleri veya bunlarin karisimlari kullanilabilir. In the invention, carbopol, carbomer, hydroxy propylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, polyacrylate polymers or their mixes can be used.
Bulusta “mikrobiyal koruyucu madde” terimi mikrobiyal aktiviteye karsi koruyan maddeler olarak ifade edilmektedir. Bahsi geçen mikrobiyal koruyucu madde olarak; sodyum benzoat, sodyum metil para hidroksibenzoat, sodyum propil para hidroksibenzoat, benzalkonyum klorit, borik asit, sorbik asit, etanol veya bunlarin karisimlari kullanilabilir. In the invention, the term "microbial preservative" protects against microbial activity. referred to as items. As the aforementioned microbial preservative; sodium benzoate, sodium methyl para hydroxybenzoate, sodium propyl para hydroxybenzoate, benzalkonium chloride, boric acid, sorbic acid, ethanol or their mixtures can be used.
Bulusta “sertlestirici ajan; terimi formülasyonlarin çesitli basinç ve kuvvetlere karsi güçlendirilmesi için kullanilan maddeler olarak ifade edilmektedir. Sertlestirici ajan olarak; setil alkol, alüminyum stearat, dimetikon, setearil alkol, stearil alkol, arap zamki, kitre zamki, aljinat, karragen, ksantan zamki, guar zamki, setostearil alkol, setil esterlerin mumu, dekstrin, gliseril monostearat, hidroksipropil selüloz, kaolin, polietilen beyaz vazelin, propilen glikol stearat, nisasta, mum, beyaz mum, bentonit, balmumu, beyaz balmumu, sentetik balmumu, parafin, beyaz kati parafin, kati vazelin, pektin, karbomer, polivinilprolidon veya bunlarin karisimlari kullanilabilir. In the invention, “hardening agent; The term means formulations against various pressures and forces. are expressed as substances used for strengthening. As a hardening agent; cetyl alcohol, aluminum stearate, dimethicone, cetearyl alcohol, stearyl alcohol, gum arabic, tragacanth gum, alginate, carrageenan, xanthan gum, guar gum, cetostearyl alcohol, cetyl esters wax, dextrin, glyceryl monostearate, hydroxypropyl cellulose, kaolin, polyethylene white petrolatum, propylene glycol stearate, starch, wax, white wax, bentonite, beeswax, white beeswax, synthetic wax, paraffin, white solid paraffin, solid petrolatum, pectin, carbomer, polyvinylpyrrolidone or mixtures thereof can be used.
Bulusta sivag olarak; makrogol türevleri, vazelin, mumla modifiye vazelin, sivi vazelin, beyaz vazelin, lanolin veya lanolin türevleri, hint yagi, hindistan cevizi yagi, zeytinyagi, pamuk tohumu yagi gibi bitkisel yaglar, polietilen glikol, parafin, anhidröz, beyaz yumusak parafin veya bunlarin karisimlari kullanilabilir. As sivag in the invention; macrogol derivatives, petrolatum, wax modified vaseline, liquid petrolatum, white petrolatum, lanolin or lanolin derivatives, castor oil, coconut oil, olive oil, vegetable oils such as cottonseed oil, polyethylene glycol, paraffin, anhydrous, white soft paraffin or their mixtures can be used.
Bulusta “salim kontrol edici ajan” olarak; polivinil asetat ftalat, polietilen glikol-polivinil alkol kopoliineri, poliakrilik asit türevleri, polisakkarit türevleri, metakrilat polimeri, polimetakrilat, etil metakrilat kopolimeri, metakrilik asit-metilmetakrilat kopolimeri, metakrilik asit-etil akrilat kopolimeri, polilaktik asit, polilaktik asit kopolimeri, polivinilpirolidon, polivinilalkol, gliserit, polietilen oksit, gliseril behenat, metakrilik asit kopolimeri, hidroksipropil metil selüloz, hidroksipropil selüloz, hidroksipropil metil selüloz asetat, karboksi metil etil selüloz, sodyum karboksi metil selüloz, etil selüloz, metil akrilat, etilakrilat, metilmetakrilat, etilmetakrilat, akrilik ve metakrilik asit esterleri, sodyum aljinat, hipromelloz ftalat, hipromelloz asetat süksinat, selüloz butirat ftalat, selüloz hidrojen ftalat, selüloz propiyanat ftalat, selüloz asetat ftalat, selüloz asetat trimelitat, jelatin, selak, ksantan zamki veya bunlarin karisiinlari kullanilabilir. As "release controlling agent" in the invention; polyvinyl acetate phthalate, polyethylene glycol-polyvinyl alcohol copolyiner, polyacrylic acid derivatives, polysaccharide derivatives, methacrylate polymer, polymethacrylate, ethyl methacrylate copolymer, methacrylic acid-methylmethacrylate copolymer, methacrylic acid-ethyl acrylate copolymer, polylactic acid, polylactic acid copolymer, polyvinylpyrrolidone, polyvinylalcohol, glyceride, polyethylene oxide, glyceryl behenate, methacrylic acid copolymer, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose acetate, carboxy methyl ethyl cellulose, sodium carboxy methyl cellulose, ethyl cellulose, methyl acrylate, ethylacrylate, methylmethacrylate, ethylmethacrylate, acrylic and methacrylic acid esters, sodium alginate, hypromellose phthalate, hypromellose acetate succinate, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propyanate phthalate, cellulose acetate phthalate, cellulose acetate Trimelitate, gelatin, celak, xanthan gum or their mixtures can be used.
Bulusta “plastifiyan” terimi, kaplamanin esnekligini arttirmak, filmin kirilma riskini azaltmak ve Iilmin çekirdege adhezyonunu arttirmak için kullanilan maddeler olarak ifade edilmektedir, Polimerle geçimli olmalari ve uçucu özellikte olmamalari gerekmektedir. In the invention, the term "plasticizer" is used to increase the flexibility of the coating, reduce the risk of film breakage. Expressed as substances used to reduce and increase the adhesion of the film to the core. They must be compatible with the polymer and not be volatile.
Plastifiyan olarak; polietilen glikoller (Makrogol), gliserin, propileii glikol, asetil sitrat, aniil oleat, miristil asetat, butil oleat, butil stearat, triasetin, dietilftalat, asetillenmis mono gliseridler veya bunlarin karisimlari kullanilabilir. As a plasticizer; polyethylene glycols (Macrogol), glycerin, propylene glycol, acetyl citrate, aniyl oleate, myristyl acetate, butyl oleate, butyl stearate, triacetin, diethylphthalate, acetylated monoglycerides or mixtures thereof may be used.
Bulusta “antiadherent” terimi, pürüzlü tablet yüzeyi olusmasini önleyen maddeler olarak ifade edilmektedir. Antiadherent olarak; talk, kolloidal silikon dioksit (Aerosil, Syloid, Cab-O-Sil), magnezyum stearat, misir nisastasi, magnezyum trisilikat veya bunlarin karisimlari kullanilabilir. In the invention, the term "antiadherent" refers to substances that prevent the formation of a rough tablet surface. is expressed. As an antiadherent; talc, colloidal silicon dioxide (Aerosil, Syloid, Cab-O-Sil), magnesium stearate, corn starch, magnesium trisilicate or their mixes can be used.
Bulusta “film yapici ajan” terimi, bir baglayicinin bir film, örnegin ince tabaka veya örtü olusturmak için gerekli komponentler olarak ifade edilmektedir. Film yapici ajan olarak; polivinil alkol-kismen hidrolize, metil selüloz, etil selüloz, hidroksipropil selüloz, hidroksietil selüloz, hidroksipropil metil selüloz, polietilen glikol, polietilen oksit, Makrogol, jelatin veya bunlarin karisimlari kullanilabilir. In the invention, the term "film-forming agent" refers to the use of a binder as a film, eg film or film. It is expressed as the necessary components to create it. As a film making agent; polyvinyl alcohol-partially hydrolyzed, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, polyethylene oxide, Macrogol, gelatin or their mixtures can be used.
Bulusta “opaklastirici madde 7” terimi, istenilen sistemi opak hale getirmek için ilave edilen maddeler olarak ifade edilmektedir. Opaklastirici madde olarak; titanyum dioksit, kalsiyum karbonat, çinko asetat, alüminyum stearat, çinko stearat veya bunlarin karisimlari kullanilabilir. In the invention, the term "opacifying agent 7" refers to the additives added to make the desired system opaque. referred to as items. As an opacifying agent; titanium dioxide, calcium carbonate, zinc acetate, aluminum stearate, zinc stearate or mixtures thereof can be used.
Bulusta “nemlendirici madde” terimi; preparat ile hava arasindaki nem miktarini düzenleyen ve kontrol eden maddeler olarak ifade edilmektedir. Nemlendirici madde olarak; gliserin, sorbitol, propilen glikol, üre, kolloidal yapidaki maddeler, likit parafin, vazelin (petrolatum), sivi vazelin, selüloz ve selüloz yapisindaki maddeler, zamklar (kitre), bazi elektrolitler (Al tuzlari, civa tuzlari borax) veya bunlarin karisimlari kullanilabilir. The term "moisturizing agent" in the invention; the amount of moisture between the preparation and the air. are referred to as regulating and controlling substances. moisturizing agent aspect; glycerin, sorbitol, propylene glycol, urea, colloidal substances, liquid paraffin, petrolatum (petrolatum), liquid petrolatum, cellulose and cellulose-containing substances, gums (tragacanth), some electrolytes (Al salts, mercury salts borax) or their mixtures can be used.
Bulusta granülasyon çözücüsü olarak satlastirilmis su, etil alkol, metil alkol, isopropil alkol, butil alkol gibi alkoller, metilen klorür veya bunlarin karisimlari kullanilabilir. In the invention, purified water, ethyl alcohol, methyl alcohol, isopropyl as granulation solvent Alcohols such as alcohol, butyl alcohol, methylene chloride or their mixtures can be used.
Bulusta ”süspansiyon ajani” terimi viskoziteyi artirmak ve çökmeyi yavaslatmak amaciyla kullanilir. Bulusta ”süspansiyon ajani” olarak, ksantan gami, guar gam, karragenan, etilselüloz, hidroksietil selüloz, hidroksipropil selüloz, polivinilpirolidon, hidroksipropil metilselüloz (HPMC), metil selüloz veya bunlarin karisimlari kullanilabilir. In the invention, the term "suspension agent" is used to increase viscosity and slow settling. used for the purpose. As a "suspension agent" in the invention, xanthan gum, guar gum, carrageenan, ethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, hydroxypropyl methylcellulose (HPMC), methyl cellulose or mixtures thereof can be used.
Bulusta “stabilizör” terimi; eklendiginde kristallenmeyi ya da faz ayrimini önleyen maddeler olarak ifade edilmektedir. Stabilizör olarak benzoik asit, edetik asit, salisilik asit, sorbik asit, sodyum dehidroasetat, tokoferol, butillenmis hidroksianisol, butillenmis hidroksitoluen, propilgallat, kastor yagi, oleil alkol, poloksamer ve poloksaminler (polioksietilen ve polioksipropilen blok kopolimeri), ksantan zamki, sorbitan yag asitleriiiin etoksillenmis esterleri, polisorbat 80 veya Tween 80 gibi polisorbatlar, etoksillenmis mono- ve digliseritler, etoksillenmis lipidler, etoksillenmis yag alkolleri veya yag asitleri, diasetil fosfat, fosfatidil gliserol, doymus veya doymamis yag asitleri, sodyum kolat, sodyum glikolat, sodyum taurokolat, paraoksibenzoik asit, etilen diainin tetraasetik asit (EDTA), dietilen triamin penta asetik asit veya bunlarin karisimlari kullanilabilir. The term "stabilizer" in the invention; prevents crystallization or phase separation when added referred to as items. Benzoic acid, edetic acid, salicylic acid as stabilizer, sorbic acid, sodium dehydroacetate, tocopherol, butylated hydroxyanisole, butylated hydroxytoluene, propylgallate, castor oil, oleyl alcohol, poloxamer and poloxamines (polyoxyethylene and polyoxypropylene block copolymer), xanthan gum, sorbitan oil ethoxylated esters of acids, polysorbates such as polysorbate 80 or Tween 80, ethoxylated mono- and diglycerides, ethoxylated lipids, ethoxylated fatty alcohols or fatty acids, diacetyl phosphate, phosphatidyl glycerol, saturated or unsaturated fatty acids, sodium cholate, sodium glycolate, sodium taurocholate, paraoxybenzoic acid, tetraacetic acid of ethylene diaine acid (EDTA), diethylene triamine penta acetic acid or mixtures thereof can be used.
Mevcut bulustaki uygun etken madde/ler ve/veya farmasötik olarak kabul edilebilir türevlerini içeren farmasötik bilesimdeki Famsiklovir ve/Veya farmasötik olarak kabul hastanin bireysel ihtiyaçlarina ve uzmanin degerlendirilmesine göre ayarlanmaktadir. Appropriate active ingredient(s) and/or pharmaceutically acceptable in the present invention Famciclovir in pharmaceutical composition containing derivatives and/or pharmaceutically acceptable It is adjusted according to the individual needs of the patient and the assessment of the specialist.
Bulus esas olarak, oral kullanilmak üzere antiviral özellikteki Famsiklovir ve/veya farmasötik olarak kabul edilebilir türevlerinin monoterapi olarak tek basina kullanildigi ve/veya bu etken maddenin diger uygun aktif ajan/lar ile kombine tedavi olarak kullanildigi farmasötik bilesim/lerin hazirlanmasi ile ilgilidir. Bulusun hazirlanan farmasötik bilesimlerinin tablet ve/veya kapsül formunda olmasi temeldir. Böylece, famsiklovir ve/veya farmasötik olarak kabul edilebilir türevleri uygun farmasötik formlarin sasirtici bir sekilde fiziksel ve kimyasal kararlilik açisindan oldukça stabil bir davranis sergiledigi gözlenmistir. The invention is mainly based on Famciclovir and/or antiviral drugs for oral use. where pharmaceutically acceptable derivatives are used alone as monotherapy and/or as a combined treatment of this active substance with other suitable active agent/s. relates to the preparation of the pharmaceutical composition(s) for which it is used. Your invention is prepared It is essential that pharmaceutical compositions are in tablet and/or capsule form. Like this, famciclovir and/or pharmaceutically acceptable derivatives of suitable pharmaceutical forms surprisingly very stable behavior in terms of physical and chemical stability has been observed.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2016/15312A TR201615312A1 (en) | 2016-10-27 | 2016-10-27 | Antiviral Pharmaceutical Compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2016/15312A TR201615312A1 (en) | 2016-10-27 | 2016-10-27 | Antiviral Pharmaceutical Compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201615312A1 true TR201615312A1 (en) | 2018-05-21 |
Family
ID=63682782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2016/15312A TR201615312A1 (en) | 2016-10-27 | 2016-10-27 | Antiviral Pharmaceutical Compositions |
Country Status (1)
Country | Link |
---|---|
TR (1) | TR201615312A1 (en) |
-
2016
- 2016-10-27 TR TR2016/15312A patent/TR201615312A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1194153B1 (en) | Taste masked pharmaceutical liquid formulations | |
JP2017536404A (en) | Gastric retention sustained release suspension composition | |
JP2004520420A (en) | Pharmaceutical compositions with masked taste | |
US20100183730A1 (en) | High dose composition of ursodeoxycholic acid | |
WO2011081199A1 (en) | Oral preparation having improved quality | |
JP2004507487A (en) | Intestinal disease drug | |
ES2901598T3 (en) | Film-coated tablet having high chemical stability of the active ingredient | |
JP4866170B2 (en) | Hypnotic controlled release pharmaceutical composition and method for producing the same | |
RU2505286C1 (en) | Pharmaceutical composition for treating hiv infection, method for preparing it, and method of treating | |
TR201615312A1 (en) | Antiviral Pharmaceutical Compositions | |
ES2331501B1 (en) | SOLID PHARMACEUTICAL COMPOSITION OF DIDANOSINE. | |
JP2008156258A (en) | Oral solid composition having covered bitterness | |
TR201612545A1 (en) | ORAL PHARMACEUTICAL COMPOSITIONS | |
WO2022196818A1 (en) | Coated solid pharmaceutical preparation | |
TR201612324A1 (en) | Pharmaceutical Compositions Used in Respiratory Tract Diseases | |
TR201613529A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
TR201612582A1 (en) | ORAL PHARMACEUTICAL COMPOSITIONS | |
TR201613452A1 (en) | FORMULATIONS FOR THE TREATMENT OF HYPERPARATHYROIDISM | |
TR201607066A1 (en) | AMINOSALICYLIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS | |
RU2543322C1 (en) | Pharmaceutical composition for treating hiv-infection, method for preparing and method of using | |
TR201611404A3 (en) | ORAL PHARMACEUTICAL COMPOSITIONS | |
TR201613300A1 (en) | ANTIMUSCARINIC PHARMACEUTICAL COMPOSITIONS | |
TR201611757A2 (en) | MUCOLITIC ORAL FORMULATIONS | |
JP5896806B2 (en) | Oral composition | |
TR201612694A1 (en) | ORAL PHARMACEUTICAL COMPOSITIONS |